Regulation of the venous tone

  • Francisc A. Schneider
  • Ioana Raluca Siska
  • Jecu Aurel Avram
Part of the Basic Science for the Cardiologist book series (BASC, volume 15)


The control of venous smooth muscle tone and venous function is dominated by the sympathetic nervous system, its activity being coordinated in the vasomotor center in the brainstem. The degree of adrenergic innervation of the veins varies widely; cutaneous and splachnic veins are most densely innervated, while large conduit veins and the deep limb veins receive only scarce adrenergic innervation (396).


Saphenous Vein Varicose Vein Hand Vein Human Saphenous Vein Venous Tone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 1992; 41: 9–18CrossRefPubMedGoogle Scholar
  2. 2.
    Aardal S, Helle KB, Elsayed S, Reed RK, Serck-Hanssen G. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 1993; 5: 405–412CrossRefPubMedGoogle Scholar
  3. 3.
    Akar F, Uydes BS, Ayrancioiglu K, Yener A, Aslamaci S, Arsan M, Tioriuner A, Kanzik I. Endothelial function of human gastroepiploic artery in comparison with saphenous vein. Cardiovasc Res 1994; 28: 500–504CrossRefPubMedGoogle Scholar
  4. 4.
    Albino-Taxeira A, Azevedo I, Branco D, Osswald W, Purine agonists prevent trophic changes caused by sympathetic denervation, Eur J Pharmacol 1990; 179: 141–149CrossRefGoogle Scholar
  5. 5.
    Aldasoro M, Medina P, Vila JM, Otero E, Martinez-Leon JB, Lluch S. Endothehum-dependent relaxation of human saphenous veins in response to vasopressin and desmopressin. J Vasc Surg 1997; 25: 696–703CrossRefPubMedGoogle Scholar
  6. 6.
    Allegra C, Pollari G, Criscuolo A. Centella asiatica extract in venous disorders of the lower limbs. Comparative clinico-instrumental studies with a placebo. Clin Ter 1981; 99: 507–513. [Article in Italian]PubMedGoogle Scholar
  7. 7.
    Allen JC, Kahn AM, Navran S. Na+-K+-ATP-ase in vascular smooth muscle. Am J Physiol 1986; 250: C536–540PubMedGoogle Scholar
  8. 8.
    Allen SP, Chester AH, Piper PJ, Sampson AP, Akl ES, Yacoub MH, Effects of leukotrienes C4 and D4 on human isolated saphenous veins. Br J Clin Pharmacol 1992; 34: 409–414PubMedGoogle Scholar
  9. 9.
    Allen SP, Chester AH, Dashwood MR, Tadjkarimi S, Piper PJ, Yacoub MH. Preferential vasoconstriction to cysteinyl leukotrienes in the human saphenous vein compared with the internal mammary artery. Implications for graft performance. Circulation 1994; 90: 515–524CrossRefPubMedGoogle Scholar
  10. 10.
    Altura BM, Altura BT. Magnesium ions and contraction of vascular smooth muscles-relationship to some vascular diseases. Federation Proc 1981: 40: 2672–2679Google Scholar
  11. 11.
    Altura BM, Altura BT, Carella A. Magnesium deficiency-induced spasma of umbilical vessels. Relationship to preeclampsia, hypertension, and growth retardation. Science Wash DC 1983; 221: 376–378CrossRefGoogle Scholar
  12. 12.
    Altura BM, Altura BT. Interactions of Mg and K on blood vessels-aspects in view of hypertension. Magnesium 1984; 3: 175–194PubMedGoogle Scholar
  13. 13.
    Anastasiou N, Allen S, Paniagua R, Chester A, Yacoub M. Altered endothelial and smooth muscle cell reactivity caused by University of Wisconsin preservation solution in human saphenous vein. J Vasc Surg 1997; 25: 713–721CrossRefPubMedGoogle Scholar
  14. 14.
    Ando SI, Imaizumi T, Harada S, Hirooka Y, Takeshita A. Atrial natriuretic peptide increases human capillary filtration and venous distensibility. J Hypertension 1992; 10: 451–457CrossRefGoogle Scholar
  15. 15.
    Angeletti RH, Aardal S, Serck-Hanssen G, Gee P, Helle KB. Vasoinhibitory activity of synthetic peptides from the amino terminus of chromogranin A. Acta Physiol Scand 1994; 152: 11–19CrossRefPubMedGoogle Scholar
  16. 16.
    Arnal JF, Tack I, Besombres JP, Pipy B, Negre-Salvayre A. Nitric oxide and superoxide anion production during endothelial cell proliferation, Am J Physiol 1996; 271: C1521–1526PubMedGoogle Scholar
  17. 17.
    Arner M, Högestatt ED, Actions of some vasodilators on isolated human hand veins. Acta Physiol Scand 1987; 130: 671–677CrossRefPubMedGoogle Scholar
  18. 18.
    Arner M, Högestatt ED. Endothelium-dependent relaxation and effects of prostacyclin, endothelin, and platelet-activating factor in human hand veins and arteries. Acta Physiol Scand 1991; 142: 165–172CrossRefPubMedGoogle Scholar
  19. 19.
    Arner M, Hogestatt ED, Uski TK. Characterization of contraction-mediating prostanoid receptors in human hand veins: effects of the thromboxane receptor antagonists BM13, 505 and AH23848, Acta Physiol Scand 1991; 141: 79–86CrossRefPubMedGoogle Scholar
  20. 20.
    Arner M, Uski T, Hogestatt ED, Arner M, Uski T, Hogestatt ED. Endothelium dependence of prostanoid-induced relaxation in human hand veins. Acta Physiol Scand 1994; 150: 267–72CrossRefPubMedGoogle Scholar
  21. 21.
    Arnold JMO, Lo IK, Response of superficial dorsal hand veins in normal subjects to locally infused angiotensin II (AII) and noradrenaline (NA), Clin Pharmacol Ther 1993; 53: 139 (abstract)Google Scholar
  22. 22.
    Avram J, Siska I-R, Măties R, Avram R, Crîsnic D. Les taux de superoxide dismutase et de glutathion dans le sang des saphenes variqueuses. Phlebologie, 1999; 52: 155–162Google Scholar
  23. 23.
    Baker VL, Chao VA, Murai JT, Zaloudek CJ, Taylor RN. Human umbilical vessels and cultured umbilical vein endothelial and smooth muscle cells lack detectable protein and mRNA encoding estrogen receptors. J Soc Gynecol Investig 1997; 4: 316–324CrossRefPubMedGoogle Scholar
  24. 24.
    Banks M, Wei CM, Kim CH, Burnett JC si Miller VM. Mechanism of relaxations to C-type natriuretic peptide in veins. Am J Physiol 1996; 217: H1907–1911Google Scholar
  25. 25.
    Bar RS, Peacock ML, Spanheimer RG, Veenstra R, Hoak JC. Differential binding of insulin to human arterial and venous endothelial cells in primary culture. Diabetes 1980;29:991–995CrossRefPubMedGoogle Scholar
  26. 26.
    Barba G, Mullen MJ, Donald A, MacAllister RJ. Determinants of the response of human blood vessels to nitric oxide donors in vivo. J Pharmacol Exp Ther. 1999; 289: 1662–1668.PubMedGoogle Scholar
  27. 27.
    Barber DA, Rubin JW, Zumbro GL, Tackett RL. The use of methylene blue as an extravascular surgical marker impairs vascular responses of human saphenous vein. J Thorac Cardiovasc Surg. 1995; 109: 21–29CrossRefPubMedGoogle Scholar
  28. 28.
    Barber DA, Wang X, Gloviczki P, Miller VM. Characterization of endothelin receptors in human varicose veins. J Vasc Surg 1997; 26: 61–69CrossRefPubMedGoogle Scholar
  29. 29.
    Barker JE, Anderson J, Treasure T, Piper PJ, Influence of endothelium and surgical preparation on responses of human saphenous vein and internal thoracic artery to angiotensin II, Br J Clin Pharmacol 1994; 38:57–62CrossRefPubMedGoogle Scholar
  30. 30.
    Bax W, Bos E, Saxena PR. Heterogeneity of endothelin/sarafotoxin receptors mediating contraction of the human isolated saphenous vein. Eur J Pharmacol 1993; 239: 267–268CrossRefPubMedGoogle Scholar
  31. 31.
    Beasley D, McGuiggin ME. Interleukin 1 induces prostacyclin-dependent increases in cyclic AMP production and does not affect cyclic GMP production in human vascular smooth muscle cells. Cytokine 1995; 7: 417–426CrossRefPubMedGoogle Scholar
  32. 32.
    Beattie DK, Gosling M, Davies AH, Powell JT. The effects of potassium channel openers on saphenous vein exposed to arterial flow. Eur J Vasc Endovasc Surg 1998;15: 244–249CrossRefPubMedGoogle Scholar
  33. 33.
    Bedarida GV, Kim D, Blaskke TF, Hoffman BB. Venodilation in Raynaud’s disease. Lancet 1993; 342: 1451–1454CrossRefPubMedGoogle Scholar
  34. 34.
    Beech DJ, Bolton TB. A voltage-dependent outward current with fast kinetics in single smooth muscle cells isolated from rabbit portal vein. J Physiol Lond 1989; 412: 397–414PubMedGoogle Scholar
  35. 35.
    Belcaro GV, Grimaldi R, Guidi G. Improvement of capillary permeability in patients with venous hypertension after treatment with TTFCA. Angiology 1990; 41: 533–540.CrossRefPubMedGoogle Scholar
  36. 36.
    Bell D, McDermott BJ. Calcitonin Gene-related Peptide in the Cardiovascular System: Characterization of Receptor populations and Their (Patho) Physiological Significance. Pharm Rev 1996; 48: 254–282Google Scholar
  37. 37.
    Belz GG, Berrmann J, Schloos J, KleinBloesem CH. The effect of oral clazapril and prazosin on the constrictor effects of locally infused angiotensin I and noradrenaline in human hand veins. Br J Clin Pharmacol 1989; 28: 608–611CrossRefPubMedGoogle Scholar
  38. 38.
    Berczi V, Greene AS, Dornyei G, Csengodi J, Hodi G, Kadar A, Monos E. Venous myogenic tone: studies in human and canine vessels. Am J Physiol 1992; 263: H315–320.PubMedGoogle Scholar
  39. 39.
    Bergqvist A, Bergqvist D, Fernö M. Estrogen and progesterone receptors in vessel walls. Biochemical and immunochemical assays. Acta Obstet Gynecol Scand 1993; 72:10–16CrossRefPubMedGoogle Scholar
  40. 40.
    Berk BC. Redox signals that regulate the vascular response to injury. Thromb Haemost 1999;82:810–817PubMedGoogle Scholar
  41. 41.
    Berry C, Hamilton CA, Brosnan J, Magill FG, Berg GA, McMurray JJV, Dominczak AF. Investigation into the sources of superoxide in human blood vessels. Angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000; 101:2206–2212CrossRefPubMedGoogle Scholar
  42. 42.
    Berti F, Rossoni G, Biasi G, Buschi A, Mandelli V, Tondo C. Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins. Prostaglandins 1990; 40: 337–350CrossRefPubMedGoogle Scholar
  43. 43.
    Bhagat K, Hingorani AD, Palacios M, Charles IG, Vallance P. Cytokine-induced venodilation in humans in vivo: e NOS masquerading as iNOS. Cardiovasc Res 1999; 41:754–764CrossRefPubMedGoogle Scholar
  44. 44.
    Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1–80PubMedGoogle Scholar
  45. 45.
    Biagi G, Coccheri S, Lapilli A, Granso F, Bizarri M, Zendron R, Piccinni L. Prostacyclin and thromboxane production in human varicose saphenous vein. Thromb Haemostasis 1987; 58: 158 (abstract)Google Scholar
  46. 46.
    Biagi G, Lapilli A, Zendron R, Piccinni L, Coccheri S. Prostanoid production in varicose veins: evidence for decreased prostacyclin with increase thromboxane A2 and prostaglandin E2 formation. Angiology 1988; 39: 1036–1042CrossRefPubMedGoogle Scholar
  47. 47.
    Bishop-Bailey D, Pepper JR, Larkin SW, Mitchell JA. Differential induction of cyclooxigenase-2 in human arterial and venous smooth muscle. Role of endogenous prostanoids. Arterioscler Thromb Vasc Biol 1998; 18: 1655–1661CrossRefPubMedGoogle Scholar
  48. 48.
    Blackman DJ, Morris-Thurgood JA, Atherton JJ, Ellis GR, Anderson RA, Cockcroft JR, Frenneaux MP. Endothelium-derived nitric oxide contributes to the regulation of venous tone in humans. Circulation 2000; 101: 165–170CrossRefPubMedGoogle Scholar
  49. 49.
    Blaustein MP, Hamlyn JM. Sodium transport inhibition, cell calcium and hypertension. The natriuretic hormone (Na+-Ca2+ exchange) hypertension hypothesis. Am J Med 1984; 77: 45–49PubMedGoogle Scholar
  50. 50.
    Blochl-Daum B, Vierhapper H, Eichler HG, Waldhausl W. Endothelin-induced venoconstriction is unaffected by type 2-diabetes: in vivo effect of histamine on the endothelin action on veins. Arch Int Pharmacodyn Ther 1992; 316: 90–96PubMedGoogle Scholar
  51. 51.
    Bo X, Sexton A, Xiang Z, Nori SL, Burnstock G. Pharmacological and histochemical evidence for P2X receptors in human umbilical vessels. Eur J Pharmacol 1998;353: 59–65CrossRefPubMedGoogle Scholar
  52. 52.
    Bodelsson M, Tornebrandt K, Arneklo-Nobin B. Effect of cooling on vascular smooth muscle response to endothelin-1 in human and rat veins. Int Angiol 1997; 16: 262–268PubMedGoogle Scholar
  53. 53.
    Bodelsson G, Sandstrom K, Wallerstedt SM, Hidestal J, Tornebrandt K, Bodelsson M. Effects of propofol on substance P-induced relaxation in isolated human omental arteries and veins. Eur J Anaesthesiol 2000; 17: 720–728PubMedGoogle Scholar
  54. 54.
    Bodmer CW, Patrick AW, How TV, Williams G. Exaggerated sensitivity to NE-induced vasoconstriction in IDDM patients with microalbuminuria. Possible etiology and diagnostic implications. Diabetes 1992; 41: 209–214CrossRefPubMedGoogle Scholar
  55. 55.
    Bonner G, Preis S, Schunk U, Wagmann M, Chrosch R, Toussaint C. Effect of bradykinin on arteries and veins in systemic and pulmonary circulation. J Cardiovasc Pharmacol 1992; 20(suppl. 9): S21–27CrossRefPubMedGoogle Scholar
  56. 56.
    Borchard U. Calcium Antagonists in Comparison: View of the Pharmacologist. J Cardiovasc Pharmacol 1994; 24: S85–91PubMedGoogle Scholar
  57. 57.
    Borland JA, Chester AH, Crabbe S, Parkerson JB, Catravas JD, Yacoub MH. Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts. J Thorac Cardiovasc Surg 1998; 116: 206–212CrossRefPubMedGoogle Scholar
  58. 58.
    Borland JA, Chester AH, Morrison KA, Yacoub MH. Alternative pathways of angiotensin II production in the human saphenous vein. Br J Pharmacol 1998; 125: 423–428CrossRefPubMedGoogle Scholar
  59. 59.
    Bougelet C, Roland IH, Ninane N, Amould T, Remachle J, Michiels C. Effect of aescine on hypoxia-induced neutrophil adherence to umbilical vein endothelium. Eur J Pharmacol. 1998; 345: 89–95.CrossRefPubMedGoogle Scholar
  60. 60.
    Boura AL, Gude NM, King RG, Mak KK, Walters WA. Characterization of thromboxane A2 receptors in the human fetal placental vessels and umbilical vein. Clin Exp Pharmacol Physiol 1986:13: 83–86.CrossRefPubMedGoogle Scholar
  61. 61.
    Bouskela E, Cyrino FZ, Marcelon G. Possible mechanisms for the inhibitory effect of Ruscus extract on increased microvascular permeability induced by histamine in hamster cheek pouch. J Cardiovasc Pharmacol 1994; 24: 281–285.PubMedGoogle Scholar
  62. 62.
    Branco D, Caramona M, Araujo D, Osswald W. The role of monoamine oxidase in the metabolism of exogenous noradrenaline by the human saphenous vein. Fundam Clin Pharmacol 1992; 6: 145–152CrossRefPubMedGoogle Scholar
  63. 63.
    Brawley L, MacDonald S, Shaw AM. Role of endothelium in classical and atypical â-adrenoceptor mediated vasorelaxation in rat isolated aorta. Br. J Pharmacol 1998; 122: 395–402Google Scholar
  64. 64.
    Brayden JE. Potassium channels in vascular smooth muscle. Clin Exp Pharmacol Physiol 1996; 23: 1069–1076CrossRefPubMedGoogle Scholar
  65. 65.
    Brinkhaus B, Lindner M, Schuppan D, Hahn EG. Chemical, pharmacological and clinical profile of the East Asian medical plant Centella asiatica. Phytomedicine 2000; 7: 427–448.CrossRefPubMedGoogle Scholar
  66. 66.
    Brock TA, Brugnara C, Canessa M, Gimbrone MA. Bradykinin and vasopressin stimulate Na+-K+-Cl-cotransport in cultured endothelial cells. Am J Physiol 1986; 250: C888–895PubMedGoogle Scholar
  67. 67.
    Bryan LJ, Cole JJ, O’Donell SR, Wanstall JC. A study designed to explore the hypothesis that beta-1 adrenoceptors are “innervated” receptors and beta-2 adrenoceptors are “hormobal” receptors. J Pharmacol Exp Ther 1981; 216: 395–400PubMedGoogle Scholar
  68. 68.
    Burroughs AK, McCormick PA. Randomized trial for variceal bleeding. Z Gastroenterol 1988; 26: 24–35PubMedGoogle Scholar
  69. 69.
    Busse R, Mulsch A, Fleming I, Hecker M. Mechanisms of nitric oxide release from the vascular endothelium. Circulation 1993; 87: V18–25Google Scholar
  70. 70.
    Calcagno D, Bei M, Ross SA, Klein A, Foegh ML. Effects of estrogen on vein grafts. J Cardiovasc Surg 1992; 33: 579–584Google Scholar
  71. 71.
    Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Idendification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factor. Circ Res 1996:78:415–423CrossRefPubMedGoogle Scholar
  72. 72.
    Cario-Toumaniantz C, Loirand G, Ladoux A, Pacaud P. P2X7 receptor activation-induced contraction and lysis in human saphenous vein smooth muscle. Circ Res 1998; 27; 83: 196–203Google Scholar
  73. 73.
    Carter AJ, Bevan JA, Hanley SP, Morgan WE, Turner DR. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis. Effect of a thromboxane synthase inhibitor. Thromb Haemostasis 1984: 51: 257–260Google Scholar
  74. 74.
    Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors. Pharm Rev 1998; 50: 279–288PubMedGoogle Scholar
  75. 75.
    Chaikouni A, Crawford FA, Kochel PJ, Olanoff LS, Haluschka PV. Human internal mammary artery produces more prostacyclin than saphenous vein. J Thorac Cardiovasc Sure 1986; 92: 88–91Google Scholar
  76. 76.
    Chester AH, O’Neil GS, Tadjakarimi S, Borland JA, Yacoub MH. Effect of peri-operative storage solution on the vascular reactivity of the human saphenous vein. Eur J Cardiothorac Surg 1993; 7: 399–404CrossRefPubMedGoogle Scholar
  77. 77.
    Chiavarelli M, Fabi F, Stati T, Chiavarelli R, Del Basso P. Effects of cardioplegic solution and their components on human saphenous vein contractility. Ann Thorac Sure 1992: 53: 455–459CrossRefGoogle Scholar
  78. 78.
    Ciuffetti G, Mannarino E, Paltriccia R, Malagigi V, Sergi F, Paulisch P, Pasqualini L, Lupattelli G. Leucocyte activity in chronic venous insufficiency. Int Angiol 1994; 13: 312–316PubMedGoogle Scholar
  79. 79.
    Civantos Calzada B, Aleixandre de Artinano A. Alpha-adrenoceptor subtypes, Pharmacol Res 2001; 44: 195–208CrossRefPubMedGoogle Scholar
  80. 80.
    Clapp LH, Tinker A. Potassium channels in the vasculature. Curr Opin Nephrol Hypertension 1988; 7: 91–98Google Scholar
  81. 81.
    Clozel M, Breu V, Burri K. Pathophysiologic role of endothelin reversed by the first orally active endothelin receptor antagonist. Nature 1993; 365: 759–761CrossRefPubMedGoogle Scholar
  82. 82.
    Cocks TM, Faulkner LN, Sudhir K, Angus J. Reactivity of endothelin 1 on human and canine large veins compared with large arteries in vitro. Eur J Pharmacol 1989; 171: 17–24CrossRefPubMedGoogle Scholar
  83. 83.
    Cohen J. Insufficience veineuse et contraception orale. Rev Fr Gynecol Obstet 1991; 86: 187–189PubMedGoogle Scholar
  84. 84.
    Coleman RA, Smith WL, Narumyia S. VIIIth International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and their Subtypes. Pharmacol Rev 1994; 46: 206–224Google Scholar
  85. 85.
    Collier JG, Nachev C, Robinson BF. Effect of catecholamines and other vasoactive substances on superficial hand veins, Clin Sci 1972; 43: 455–467PubMedGoogle Scholar
  86. 86.
    Collier J, Lorge RE, Robinson BF. Comparison of effects of tolmexoside (RX71107), diazoxide, hydralazine, prazosin, glyceriltrinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins in man. Br J Pharmacol 1978; 5: 35–44CrossRefGoogle Scholar
  87. 87.
    Collier J, Vallance P. Endothelium-derived relaxing factor is an endogenous vasodilator in man. Br J Pharmacol 1989, 97: 639–641CrossRefPubMedGoogle Scholar
  88. 88.
    Collier J, Vallance P. L-NMMA increase arteriolar but not venous tone in humans: The mechansim appears to be independent of sympathetic tone, J Cardiovasc Pharmacol 1991; 17(Suppl. 3):S182–185CrossRefGoogle Scholar
  89. 89.
    Collins P, Meale CM, Rosano MC. Oestrogen as a calcium channel blocker. Eur Heart J 1996; 17(suppl D): 27–31CrossRefPubMedGoogle Scholar
  90. 90.
    Communi D, Parmentier M, Boeynaems JM. Les recepteurs P2: une famille en pleine expansion. MedSci 1996; 12: 614–619Google Scholar
  91. 91.
    Cordi AA, Lacoste JM, Descombes JJ, Courchay C, Vanhoutte PM, Laubie M, Verbeuren TJ. Design, synthesis, and structure-activity relationships of a new series of alpha-adrenergic agonists: spiro [(1,3 - diazacyclopent - 1 - ene) - 5,2 ’- (1’, 2’, 3’, 4 ’-tetrahydronaphthalene)]. J Med Chem 1995; 38: 4056–4069CrossRefPubMedGoogle Scholar
  92. 92.
    Corriu C, Feletou M, Canet E, Vanhoutte PM. Endothelium-derived factors and hypepolarizations of isolated carotid artery of the guinea pig. Br J Pharmacol 1996; 119:959–964CrossRefPubMedGoogle Scholar
  93. 93.
    Corriu C, Feletou M, Canet E, Vanhoutte PM. Inhibitors of the cytochrome P-450monooxygenase and endothelium-dependent hyperpolarizations in the guinea pig isolated carotid artery. Br J Pharmacol 1996;107: 607–610CrossRefGoogle Scholar
  94. 94.
    Cospite M. Double blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994; 45: 566–573.PubMedGoogle Scholar
  95. 95.
    Costello KB, Stewart DJ, Baffour R. Endothelin is a potent constrictor of human vessels used in coronary revascularization surgery. Eur J Pharmacol 1990; 186: 311–314CrossRefPubMedGoogle Scholar
  96. 96.
    Cox RH, Katzka D, Morad M. Characteristics of calcium currents in rabbit portal vein myocytes. Am J Physiol 1992; 263: H453–463PubMedGoogle Scholar
  97. 97.
    Cracowski JL, Stanke-Labesque F, Sessa C, Hunt M, Chavanon O, Devillier P, Bessard G. Functional comparison of the human isolated femoral artery, internal mammary artery, gastroepiploic artery, and saphenous vein. Can J Physiol Pharmacol 1999; 77: 770–776CrossRefPubMedGoogle Scholar
  98. 98.
    Cracowski JL, Stanke-Labesque F, Chavanon O, Corompt E, Veitl S, Blin D, Bessard G, Devillier P. Thromboxane A(2) modulates cyclic AMP relaxation and production in human internal mammary artery. Eur J Pharmacol 2000; 387: 295–302CrossRefPubMedGoogle Scholar
  99. 99.
    Craven PA, DeRubertis FR. Restoration of the responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemeproteins. Evidence for involvement of the paramagnetic nitrosyl-heme complex in enzyme activation. J Biol Chem. 1978; 253: 8433–8443.PubMedGoogle Scholar
  100. 100.
    Creager MA, Liang C, Coffman JD. Beta-adrenergic mediated vasodilator response to insulin in the human forearm. J Pharmacol Exp Ther 1985; 235: 709–714PubMedGoogle Scholar
  101. 101.
    Crossman D, McEwan J, MacDermot J, Maclntyre I, Dollery CT. Human calcitonin gene-related peptide activates adenylate cyclase and releases prostacyclin from human umbilical vein endothelial cells. Br J Pharmacol. 1987; 92: 695–701.CrossRefPubMedGoogle Scholar
  102. 102.
    Crowe R, Burnstock G, Dickinson IK, Pryor JP. The human penis: an unusual penetration of NPY-immunoreactive nerves within the medial muscle coat of the deep dorsal vein. J Urol 1991; 145: 1292–1296PubMedGoogle Scholar
  103. 103.
    Cruz MA, Gonzalez C, Sepulveda WH, Rudolph MI. Effect of histamine on human placental chorionic veins: interaction with serotonin. Pharmacology 1991; 42: 86–90.CrossRefPubMedGoogle Scholar
  104. 104.
    Cruz MA, Gallardo V, Miguel P, Carrasco G, Gonzalez C. Serotonin-induced vasoconstriction is mediated by thromboxane release and action in the human fetal-placental circulation. Placenta 1997; 18: 197–204.CrossRefPubMedGoogle Scholar
  105. 105.
    Curtis SB, Hewitt J, Yakubovitz S, Anzarut A, Hsiang YN, Buchan AM. Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol Heart Circ Physiol 2000; 278: H1815–1822PubMedGoogle Scholar
  106. 106.
    Daly RN, Hieble JP. Neuropeptide Y modulates adrenergic neurotransmission by an endothelium dependent mechanism. Eur J Pharmacol. 1987; 138: 445–446.CrossRefPubMedGoogle Scholar
  107. 107.
    Danesi R, Del Tacca M. The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism 1996; 45(8 Suppl 1): 49–50CrossRefPubMedGoogle Scholar
  108. 108.
    Danser JAH. Local Renin-angiotensin systems. Moll Cell Biochem 1996; 157: 211–216CrossRefGoogle Scholar
  109. 109.
    Davenport AP, Kuc RE, Maguire JJ, Harland SP. ETA receptors predominate in the human vasculature and mediate constriction. J Cardiovasc Pharmacol 1995; 26 (Suppl 3): S265–267PubMedGoogle Scholar
  110. 110.
    Davenport AP, Kuc RE, Mockridge JW. Endothelin-converting enzyme in the human vasculature: evidence for differential conversion of big endothelin-3 by endothelial and smooth-muscle cells. J Cardiovasc Pharmacol 1998; 83: S1–3CrossRefGoogle Scholar
  111. 111.
    Dawes M, Chowienczyk PJ, Ritter JM. Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by â-adrenergic agonists in human forearm. Circulation 1997; 95: 2293–2297CrossRefPubMedGoogle Scholar
  112. 112.
    De Moura RS, Jasbik W. Actions of cromakahm in isolated human saphenous vein. Hypertension 1992; 19(2 Suppl):II121–124CrossRefPubMedGoogle Scholar
  113. 113.
    Dhein S, Reiss N, Gerwin R, Borowski A, Korb H, Klaus W, de Vivie ER. Endothelial function and contractility of human vena saphena magna prepared for aortocoronary bypass grafting. Thorac Cardiovasc Surg 1991; 39: 66–69CrossRefPubMedGoogle Scholar
  114. 114.
    Diehl NL, Shreeve SM. Identification of the alpha lc-adrenoceptor in rabbit arteries and the human saphenous vein using the polymerase chain reaction. Eur J Pharmacol 1994; 268: 393–398CrossRefPubMedGoogle Scholar
  115. 115.
    Dimech J, Feniuk W, Latimer RD, Humphrey PP. Somatostatin-induced contraction of human isolated saphenous vein involves sst2 receptor-mediated activation of L-type calcium channels. J Cardiovasc Pharmacol 1995; 26: 721–728CrossRefPubMedGoogle Scholar
  116. 116.
    Docherty JR. Aging and vasoconstrictor responses mediated by alpha 2-adrenoceptors and 5-HT1 and 5-HT2 receptors. Ann N Y Acad Sci 1994; 717: 282–292CrossRefPubMedGoogle Scholar
  117. 117.
    Docherty JR. Subtypes of functional alphal-and alpha2-adrenoceptors. Eur J Pharmacol. 1998; 361: 1–15.CrossRefPubMedGoogle Scholar
  118. 118.
    Drouet L, Baudin B, Baumann FC, Caen JP. Serum angiotensin-converting enzyme. An endothelial cell marker. J Lab Clin Med 1988; 112: 450–457PubMedGoogle Scholar
  119. 119.
    Dubiak GR, El-Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol 1993; 265: C577–606Google Scholar
  120. 120.
    Dzau VJ, Re R., Tissue Angiotensin System in Cardiovascular Medicine. A Paradigm Shift? Circulation 1994; 89: 493–498CrossRefPubMedGoogle Scholar
  121. 121.
    Edvinsson L, Hakanson R, Steen S, Sundler F, Uddman R, Wahlestedt C, Edvinsson L, Hakanson R, Steen S, Sundler F, Uddman R, Wahlestedt C, Innervation of human omental arteries and veins and vasomotor response to noradrenaline, neuropeptide Y, substance P and vasoactive intestinal peptide. Regul Pept 1985; 12: 67–79CrossRefPubMedGoogle Scholar
  122. 122.
    Edwards RM, Stack EJ, Trizna W. CGRP stimulates adenylate cyclase and relaxes intracerebral arterioles. J Pharmacol Exp Ther 1991; 257: 1020–1024PubMedGoogle Scholar
  123. 123.
    Eglen RM, Hedge SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharm Rev 1996; 48: 532–556Google Scholar
  124. 124.
    Eichler HG, Blochl-Daum B, Kyrle PA, Gasic S. Cilazapril and enalapril inhibit local angiotensin I conversion in human veins but lack direct venodilating properties. J Cardiovasc Pharmacol 1989; 14: 248–252CrossRefPubMedGoogle Scholar
  125. 125.
    Eichler HG, Blaschke TF, Hoffman BB. Decreased responsiveness of superficial hand veins to phenylephrine in black normotensive males. J Cardiovasc Pharmacol 1990; 16: 177–181CrossRefPubMedGoogle Scholar
  126. 126.
    Eichler HG, Blaschke TF, Kraemer FB, Ford GA, Blochl-Daum B, Hoffman BB. Responsiveness of superficial hand veins to cc-adrenoceptor agonists in insulin-dependent diabetic patients. Clin Sci 1992; 82: 163–168PubMedGoogle Scholar
  127. 127.
    Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995; 270: 15262–15268CrossRefPubMedGoogle Scholar
  128. 128.
    Enero MA, Saidman BQ. Possible feedback inhibition of noradrenaline release by purine compounds. Naunyn Schmiedebergs Arch Pharmacol 1977;297: 39–46CrossRefPubMedGoogle Scholar
  129. 129.
    Enero MA. Further evidence for the purinergic inhibition of adrenergic neurotransmission in the rat portal vein. Acta Physiol Lat Am 1981; 31: 93–103PubMedGoogle Scholar
  130. 130.
    Ergul A, Shoemaker K, Puett D, Tackett RL. Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. J Pharmacol Exp Ther 1998; 285:511–517PubMedGoogle Scholar
  131. 131.
    Escobales N, Longo E, Cragoe EJ, Danthuluri NR, Brock T. Osmotic activation of Nail exchange in human endothelial cells. Am J Physiol 1990; 259: C640–646PubMedGoogle Scholar
  132. 132.
    Fabricius AM, Oser A, Diegeler A, Rauch T, Mohr FW. Endothelial function of human vena saphena magna prepared with different minimally invasive harvesting techniques. Eur J Cardiothorac Surg 2000; 18: 400–403CrossRefPubMedGoogle Scholar
  133. 133.
    Facino RM, Carini M, Stefani R. Anti-elastase and anti-hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency. Arch Pharm (Weinheim) 1995;328: 720–724.CrossRefGoogle Scholar
  134. 134.
    Falkenhahn M, Gohlke P, Paul M. The Renin-Angiotensin System in the Heart and Vascular Wall: New Therapeutic Aspects. J Cardiovasc Pharm 1994; 24(suppl 2): S6–13Google Scholar
  135. 135.
    Farhat MY, Abi-Younes S, Dingaan B, Vargas R, Ramwell PW. Estradiol increases cyclic adenosine monophosphate in rat pulmonary vascular smooth muscle cells by a nongenomic mechanism. J Pharmacol Exp Ther 1996; 276: 652–657PubMedGoogle Scholar
  136. 136.
    Feelisch M. Biotransformation to nitric oxide of organic nitrates - comparison to other nitrovasodilators. Eur Heart J 1993; 14: I123–132Google Scholar
  137. 137.
    Feldman RD, Bierbrier GS. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass, Lancet 1993; 342: 707–709CrossRefPubMedGoogle Scholar
  138. 138.
    Feletou M, Martin CA, Molimard M, Naline E, Germain M, Thurieau C, Fauchere JL, Canet E, Advenier C. In vitro effects of HOE 140 in human bronchial and vascular tissue. Eur J Pharmacol 1995; 274:57–64CrossRefPubMedGoogle Scholar
  139. 139.
    Feletou M, Vanhoutte PM. The alternative: EDHF. J Moll Cell Cardiol 1999; 31: 15–22CrossRefGoogle Scholar
  140. 140.
    Ferro A, Kaumann AJ, Brown MJ. Beta 1- and beta 2-adrenoceptor-mediated relaxation in human internal mammary artery and saphenous vein: unchanged beta-and alpha-adrenoceptor responsiveness after chronic beta 1-adrenoceptor blockade. Br J Pharmacol 1993; 109: 1053–1058CrossRefPubMedGoogle Scholar
  141. 141.
    Ferro A, Queen LR, Priest RM, Xu B, Ritter JM, Poston L, Ward JPT. Activation of the nitric oxide synthase by â2-adrenoceptors in human umbilical vein endothelium in vitro. Br J Pharmacol 1999; 126: 1872–1880CrossRefPubMedGoogle Scholar
  142. 142.
    Figueroa R, Omar HA, Tejani N, Wolin MS. Gestational diabetes alters human placental vascular responses to changes in oxygen tension. Am J Obstet Gynecol 1993; 168: 1616–1622PubMedGoogle Scholar
  143. 143.
    Figueroa R, Martinez E, Fayngersh RP, Jiang H, Omar HA, Tejani N, Wolin MS. Absence of relaxation to lactate in human placental vessels of pregnancies with severe preeclampsia. Am J Obstet Gynecol 1995; 173: 1800–1806CrossRefPubMedGoogle Scholar
  144. 144.
    Flavahan NA, Vanhoutte PM. Sympathetic purinergic vasoconstriction and thermosensitivity in acanine cutaneous vein. J Pharm Exp Ther 1986; 239: 784–789Google Scholar
  145. 145.
    Flavahan NA, Miller VM, Aarhus LL, Vanhoutte PM. Dennervation augments alpha-2 but not alpha-1 adrenergic responses in canine saphenous vein. J Pharmacol Exp Ther 1987; 240: 589–593PubMedGoogle Scholar
  146. 146.
    Flavahan NA, Shimokawa H, Vanhoutte PM. Pertussis toxin inhibits endothelium-dependent relaxations to certain antagonists in porcine coronary arteries J Physiol 1989:408:549–560PubMedGoogle Scholar
  147. 147.
    Fleming I, Bauersachs J, Busse R. Pracrine functions of the coronary vascular endothelium. Moll Cell Biochem 1996; 157: 137–145CrossRefGoogle Scholar
  148. 148.
    Foegh ML, Ramwell PW. Cardiovascular effects of estrogen: implications of the discovery of the estrogen receptor subtype beta. Curr Opin Nephr Hypertens 1998; 7: 83–89Google Scholar
  149. 149.
    Ford GA, Hoffman BB, Vestal RE, Blaschke TF. Age-related changes in adenosine and beta-adrenoceptor responsiveness of vascular smooth muscle in man. Br J Clin Pharmacol 1992; 33: 83–87CrossRefPubMedGoogle Scholar
  150. 150.
    Franco-Cereceda A, Liska J. Neuropeptide Y Yl receptors in vascular pharmacology. Eur J Pharmacol 1998; 349: 1–14CrossRefPubMedGoogle Scholar
  151. 151.
    Freeman JE, Kuo WY, Milligan G, Lowenstein CJ, Levine MA, Flavahan NA. Analysis of the pertussis toxin-sensitive receptor: G protein interactions in native porcine endothelial cells. Endothelium 1995; 3:321–330CrossRefGoogle Scholar
  152. 152.
    Fridovich I. Fundamental aspects of reactive oxygen species, or what’s the matter with oxygen? Ann N Y Acad Sci 1999; 893:13–18CrossRefPubMedGoogle Scholar
  153. 153.
    Fried G, Samuelson U. Endothelin and neuropeptide Y are vasoconstrictors in human uterine blood vessels. Am J Obstet Gynecol 1991; 164: 1330–1336PubMedGoogle Scholar
  154. 154.
    Furci L, Fitzgerald DJ, Fitzgerald GA. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation. J Pharmacol Exp Ther 1991; 258: 74–81PubMedGoogle Scholar
  155. 155.
    Gardner DG. Molecular Biology of Natriuretic Peptides. TCM 1994; 4: 159–164PubMedGoogle Scholar
  156. 156.
    Gavin KT, Colgan MP, Moore D, Shanik G, Docherty JR. Alpha 2C-adrenoceptors mediate contractile responses to noradrenaline in the human saphenous vein. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 406–411CrossRefPubMedGoogle Scholar
  157. 157.
    Glowinski J, Glowinski S. Role of oxygen-derived free radicals in pathogenesis of varicose veins. Przeglad Flebologiczny 2000; 8: 5–9 (abstract)Google Scholar
  158. 158.
    Glusa E, Muller-Schweinitzer E. Heterogeneity of 5-HT receptor subtypes in isolated human femoral and saphenous veins, Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 133–136CrossRefPubMedGoogle Scholar
  159. 159.
    Goodfraind TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists New Engl J Med 1995; 334: 1649–1654Google Scholar
  160. 160.
    Goodrich SM, Wood JE. Peropheral venous distensibility and velocity of venous blood flow during pregnancy or during oral contraceptive therapy. Am J Obstet Gynecol 1964; 90: 740–744PubMedGoogle Scholar
  161. 161.
    Gorenne I, Labat C, Gascard JP, Brink C. Antigen stimulation of human pulmonary smooth muscle: an in vitro model of inflammation. Cell Biol Toxicol 1996; 12: 239–44CrossRefPubMedGoogle Scholar
  162. 162.
    Gothert M, Molderings GJ, Fink K, Schlicker E. Heterogeneity of presynaptic serotonin receptors on sympathetic neurones in blood vessels. Blood Vessels. 1991; 28: 11–18.PubMedGoogle Scholar
  163. 163.
    Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of Protein-kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arteriscler Thromb Vasc Biol 2000; 20: 2175–2183CrossRefGoogle Scholar
  164. 164.
    Grunenberger F. Calcitonin gene-related peptide (CGRP): a vasodilator neuropeptide with many potential applications. Pathol Biol (Paris). 1993; 41: 936–942Google Scholar
  165. 165.
    Guillaume M, Padioleau F. Veinotonic effect, vascular protection, antiinflammatory and free radical scavenging properties of horse chestnut extract. Arzneimittelforschung 1994; 44: 25–35.PubMedGoogle Scholar
  166. 166.
    Guimaraes S, Moura D. Vascular Adrenoceptors: An Update. Phamacol Rev 2001; 53: 319–356Google Scholar
  167. 167.
    Haefeli WE, Srivastava N, Kongpatanakul S, Blaschke TF, Hoffman BB. Lack of role of endothelium-derived relaxing factor in effects of alpha-adrenergic agonists in cutaneous veins in humans. Am J Physiol 1993; 264: H364–369PubMedGoogle Scholar
  168. 168.
    Haegerstrand A, Dalsgaard CJ, Jonzon B, Larsson O, Nilsson J., Calcitonin gene-related peptide stimulates proliferation of human endothelial cells, Proc Natl Acad Sci USA. 1990;87:3299–3303.CrossRefPubMedGoogle Scholar
  169. 169.
    Hamilton CA, Reid JL. The effect of 6-hydroxydopamine on rabbit peropheral alpha adrenoceptors in vivo and in vitro. Br J Pharmacol 1981; 72: 119PCrossRefGoogle Scholar
  170. 170.
    Hamilton CA, Berg G, Mcintyre M, Mcphaden AR, Reid JL, Dominiczak AF. Effects of nitric oxide and superoxide on relaxation in human artery and vein. Atherosclerosis 1997;133:77–86CrossRefPubMedGoogle Scholar
  171. 171.
    Hanley SP, Bevan J. Inhibition by aspirin of human arterial and venous prostacyclin synthesis. Prostaglandin Leukotriene Med 1985; 20: 141–149CrossRefGoogle Scholar
  172. 172.
    Harada K, Ohashi K, Kumagai Y, Ohmon M, Fujimura A. Influence of age on venodilator effect of isoproterenol and amrinone. Eur J Clin Pharmacol 1996; 50: 37–40CrossRefPubMedGoogle Scholar
  173. 173.
    Harker CT, Ousley PJ, Harris EJ, Edwards JM, Taylor LM, Porter JM. The effects of cooling on human saphenous vein reactivity to adrenergic agonists. J Vasc Surg 1990; 12: 45–49PubMedGoogle Scholar
  174. 174.
    Harker CT, Bowman CJ, Taylor LM Jr, Porter JM. Cooling augments human saphenous vein reactivity to electrical stimulation. J Cardiovasc Pharmacol 1994; 23: 453–457PubMedGoogle Scholar
  175. 175.
    Haynes DF, Kersten MD, Rish DS, Kadowitz PJ, McNamara DB. Increased prostacyclin (PGI2) on thromboxane A2 (TxA2) formation by segments of varicose vein. Br J Surg 1988; 75: 1236–1240Google Scholar
  176. 176.
    Haynes WG, Clarke JG, Cockcroft JR, Webb DJ. Pharmacology of endothelin-1 in vivo in humans. J Cardiovasc Pharmacol. 1991; 17 Suppl 7: S284–286PubMedGoogle Scholar
  177. 177.
    Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344: 852–854CrossRefPubMedGoogle Scholar
  178. 178.
    Haynes WG. Endothelins as regulators of vascular tone in man, Clin Sci 1995; 88: 509–517PubMedGoogle Scholar
  179. 179.
    Haynes WG, Moffat S, Webb DJ. An investigation into the direct and indirect venoconstrictor effects of endothelin-1 and big endothelin-1 in man. Br J Clin Pharmacol 1995; 40: 307–311CrossRefPubMedGoogle Scholar
  180. 180.
    He GW, Rosenfeldt FL, Angus JA. Pharmacological relaxation of the saphenous vein during harvesting for coronary artery bypass grafting. Ann Thorac Surg 1993; 5: 1210–1217CrossRefGoogle Scholar
  181. 181.
    Henderson AH. Endothelium in control. Br Heart J 1991; 65: 116–125CrossRefPubMedGoogle Scholar
  182. 182.
    Herbst WM, Eberle KP, Ozen Y, Hornstein OP. The innervation of the great saphenous vein: an immunohistochemical study with special regard to regulatory peptides. Vasa 1992;21:253–257PubMedGoogle Scholar
  183. 183.
    Hicks RCJ, Golledge J, Mir-Hasseine R, Poewll JT. Vasoactive effects of fibrinogen on saphenous vein. Nature 1996; 379: 818–820CrossRefPubMedGoogle Scholar
  184. 184.
    Hicks RC, Moss J, Higman DJ, Greenhalgh RM, Powell JT. The influence of diabetes on the vasomotor responses of saphenous vein and the development of infra-inguinal vein graft stenosis. Diabetes 1997; 46: 113–118CrossRefPubMedGoogle Scholar
  185. 185.
    Higman DJ, Greenhalgh RM, Powell JT. Smoking impairs endothelium-dependent relaxation of saphenous vein. Br J Surg 1993; 80: 1242–1245CrossRefPubMedGoogle Scholar
  186. 186.
    Hiraoka W, Vazquez N, Nieves-Neira W, Chanock SJ, Pommier Y. Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells. J Clin Invest 1998; 102: 1961–1968CrossRefPubMedGoogle Scholar
  187. 187.
    Holm P, Franco-Cereceda A. Tissue concentrations of endothelins and functional effects of endothelin-receptor activation in human arteries and veins. J Thorac Cardiovasc Surg 1996; 112: 264–272CrossRefPubMedGoogle Scholar
  188. 188.
    Howard AB, Alexander RW1, Taylor WR. Effects of magnesium on nitric oxide synthase activity in endothelial cells. Am J Physiol 1995; 269: C612–618PubMedGoogle Scholar
  189. 189.
    Hu RM, Levin ER, Pedram A, Frank HJ. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 1993; 42: 351–358.CrossRefPubMedGoogle Scholar
  190. 190.
    Hull RW, Hasbargen JA, Fall S, O’Barr TP. Conjugated estrogens reduce endothelial prostacyclin production and fail to reduce postbypass blood loss. Chest 1991; 99: 1116–1119CrossRefPubMedGoogle Scholar
  191. 191.
    Hume JR, Leblanc N. Macroscopic K+ currents in single smooth muscle cells of the rabbit portal vein. J Physiol Lond 1989; 413: 49–73PubMedGoogle Scholar
  192. 192.
    Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987; 61: 866–879CrossRefPubMedGoogle Scholar
  193. 193.
    Ignarro LJ. Heme-dependent activation of guanilate-cyclase by nitric oxide: a nivel signal transduction mechanism. Blood Vessels 1991; 28: 67–73PubMedGoogle Scholar
  194. 194.
    Inoue R, Okabe K, Kitamura K, Kuriyama H. Two Ca2+ -dependent K+ -channels classified by the application of tetraethylammonium distribute to smooth muscle membrane of single cells dispersed from the rabbit portal vein. Pfluegers Arch 1986; 406: 138–143CrossRefGoogle Scholar
  195. 195.
    Iversen PO, Nicolaysen A, Kvernebo K, Benestad HB, Nicolaysen G. Human cytokines modulate arterial vascular tone via endothelial receptors. Pflugers Arch 1999; 439: 93–100CrossRefPubMedGoogle Scholar
  196. 196.
    Izhar U, Hasdai D, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro. Coron Artery Dis 2000; 11:69–76CrossRefPubMedGoogle Scholar
  197. 197.
    Jilma B, Wolzt H, Wagner OF, Zweytek B, Monitzer B, Schuller-Petrovic S, Eichler HG. In vivo study of the effect of exogenous estradiol on α-adrenoceptor responsiveness of human veins. J Cardiovasc Pharmacol 1994; 23: 859–863CrossRefPubMedGoogle Scholar
  198. 198.
    Kajioka S, Oike M, Kitamura K. Nicorandil opens a calcium-dependent potassium channel in smooth muscle cells from rat portal vein. J Pharmacol Exp Ther 1990; 254; 905–913PubMedGoogle Scholar
  199. 199.
    Kalsner S. Cholinergic constriction in the general circulation and its role in coronary artery spasm. Circ Res. 1989; 65: 237–257.CrossRefPubMedGoogle Scholar
  200. 200.
    Karaki H, Ozaki H, Hori M, Mitsui-Sato M, Amano K-I, Hrada K-I, Miyamoto S, Nakazawa H, Won K-J, Sato K. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev 1997: 49: 158–220Google Scholar
  201. 201.
    Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994; 89: 1943–1950CrossRefPubMedGoogle Scholar
  202. 202.
    Karas RH, Baur WE, van Eickles M, Mendelsohn ME. Human vascular smooth muscle cells express an estrogen receptor isoform. FEBS Lett 1995; 377: 103–108CrossRefPubMedGoogle Scholar
  203. 203.
    Karasu C, Soncul H, Altan VM. Effects of non-insulin dependent diabetes mellitus on the reactivity of human internal mammary artery and human saphenous vein. Life Sci 1995;57:103–112CrossRefPubMedGoogle Scholar
  204. 204.
    Khansarinia S, Dennis J, Sekharan J, Veldenz H, Ceithaml E, Edwards F. Cytoprotective effects of nitric oxide and superoxide dismutase on ischemic saphenous vein endothelium. Jacksonville Medicine 2000; 295 (abstract)Google Scholar
  205. 205.
    Kirkeby HJ, Andersson KE, Forman A. Comparison of the effects of prostanoids on human penile circumflex veins and corpus cavernosum tissue. Br J Urol 1993; 72: 220–225PubMedGoogle Scholar
  206. 206.
    Kohno M, Yasunari K, Yokokawa K, Murkawa K, Horio T, Takeda T. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest 1991; 87: 1999–2004CrossRefPubMedGoogle Scholar
  207. 207.
    Komori K, Vanhoutte PM. Endothelium-derived hyperpolarizing factor. Blood Vessels 1990; 27: 238–245PubMedGoogle Scholar
  208. 208.
    Krasner LJ, Wendling WW, Cooper SC, Chen D, Hellmann SK, Eldridge CJ, McClurken JB, Jeevanandam V, Carlsson C. Direct effects of triiodothyronine on human internal mammary artery and saphenous veins. J Cardiothorac Vasc Anesth 1997; 11:463–466CrossRefPubMedGoogle Scholar
  209. 209.
    Kummer W, Haberberger R. Extrinsic and intrinsic cholinergic systems of the vascular wall. Eur J Morphol. 1999; 37: 223–226.CrossRefPubMedGoogle Scholar
  210. 210.
    Kuriyama H, Kitamura K, Nabata H. Pharmacological and Physiopathological significance of ion channels and factors that modulate them in vascular tissues. Pharm Rev 1995; 47: 387–573PubMedGoogle Scholar
  211. 211.
    Langer SZ. Presynaptic regulation of the releaser of catecholamines. Pharmacol Rev 1981;32:337–362Google Scholar
  212. 212.
    Laufs U, La Fata V, Plutzky J, Liao JK. Effect of solutions of preservation on the vascular reactivity of human saphenous veins. Ann Chir 1995; 97: 728–734Google Scholar
  213. 213.
    Lawrie GM. Endothelial preservation in human saphenous veins (letter). J Thorac Cardiovasc Surg 1990; 100: 149–150PubMedGoogle Scholar
  214. 214.
    Le SQ, Wasserstrum N, Mombouli JV, Vanhoutte PM. Contractile effect of endothelin in human placental veins: role of endothelium prostaglandins and thromboxane. Am J Obstet Gynecol 1993; 169: 919–924PubMedGoogle Scholar
  215. 215.
    Lebrec D. Portal hypertension. Serotonin and pathogenesis. Cariovasc Drugs Ther 1990; 4: 33–35CrossRefGoogle Scholar
  216. 216.
    Li Q, Feenstra M, Pfaffendorf M, Eijsman L, van Zwieten PA, Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein, J Cardiovasc Pharmacol 1997; 29: 451–456CrossRefPubMedGoogle Scholar
  217. 217.
    Li WG, Miller FJ Jr, Zhang HJ, Spitz DR, Oberley LW, Weintraub NL H202-induced 02 production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. J Biol Chem 2001; 276: 29251–29256CrossRefPubMedGoogle Scholar
  218. 218.
    Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-Converting Enzyme Inhibitors. Pharm Rev 1995; 47: 25–49PubMedGoogle Scholar
  219. 219.
    Liu ZG, Ge ZD, He GW. Difference in endothelium-derived hyperpolarizing factor-mediated hyperpolarization and nitric oxide release between human internal mammary artery and saphenous vein. Circulation 2000; 102(Suppl 3): III296–301PubMedGoogle Scholar
  220. 220.
    Loirand G, Mironneau C, Mironneau J, Pacaud P. Two types of calcium currents in single smooth muscle cells from rat portal vein. J Physiol Lond 1989; 412: 333–349PubMedGoogle Scholar
  221. 221.
    Loirand G, Pacaud P. Mechanism of the ATP-induced rise in cytosolic Ca2+ in freshly isolated smooth muscle cells from human saphenous vein. Pflugers Arch 1995; 430: 429–436CrossRefPubMedGoogle Scholar
  222. 222.
    Lowell RC, Gloviczki P, Miller VM. In vitro evaluation of endothelial and smooth muscle function of primary varicose veins. J Vasc Surg 1992; 16: 679–686CrossRefPubMedGoogle Scholar
  223. 223.
    Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 2001; 280: C719–741PubMedGoogle Scholar
  224. 224.
    Lüscher TF, Diedrich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L, Yang Z, Turina M, Gradel E, Weber E, Bühler FR. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. New Engl J Med 1988; 319: 462–467CrossRefPubMedGoogle Scholar
  225. 225.
    Lüscher TF, Yang Z, Tschudi M, von Segesser L, Stulz P, Boulanger C, Siebenmann R, Turina M, Bühler FR, Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res 1990; 66: 1088–1094CrossRefPubMedGoogle Scholar
  226. 226.
    Luthra A, Borkowski KR, Carruthers SG. Genetic aspects of variability in superficial vein responsiveness to norepinephrine, Clin Pharmacol Ther 1991; 49: 355–361CrossRefPubMedGoogle Scholar
  227. 227.
    Luthra A, Borkowski KR, Carruthers SG. Variability of superficial vein responsiveness to noradrenaline. Clin Paharmacol Ther 1990; 47: 178–180Google Scholar
  228. 228.
    Luu TN, Chester AH, O’Neil GS, Tadjkarimi S, Yacoub MH. Effects of vasoactive neuropeptides on human saphenous veins. Br Heart J 1992; 67: 474–477CrossRefPubMedGoogle Scholar
  229. 229.
    MacAllister RJ, Calver AL, Riezebos J, Collier J, Vallance P. Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery. J Pharmacol Exp Ther 1995; 273: 154–60PubMedGoogle Scholar
  230. 230.
    Maguire JJ, Johnson CM, Mockridge JW, Davenport AP. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle. Br J Pharmacol 1997; 122: 1647–1654CrossRefPubMedGoogle Scholar
  231. 231.
    Maigaard S, Forman A, Andersson KE. Differential effects of angiotensin, vasopressin, and oxytocin on various smooth muscle tissues within the human uteroplacental unit. Acta Physiol Scand 1986; 128: 23–31CrossRefPubMedGoogle Scholar
  232. 232.
    Mais DE, Dunlap C, Hamanaka N, Halushka PV. Further studies on the effects of epimers of thromboxane A2 antagonists on platelets and veins. Eur J Pharmacol. 1985; 111: 125–128.CrossRefPubMedGoogle Scholar
  233. 233.
    Mak KK, Gude NM, Walters WA, Boura AL. Effects of vasoactive autacoids on the human umbilical-fetal placental vasculature. Br J Obstet Gynaecol 1984; 91: 99–106CrossRefPubMedGoogle Scholar
  234. 234.
    Malmqvist U, Arner A, Uvelius B. Lactate dehydrogenase activity and isoform distribution in normal and hypertrophic smooth muscle tissue from the rat. Pfluegers Arch, 1991; 419: 230–234CrossRefGoogle Scholar
  235. 235.
    Mangiafico RA, Malatino LS, Santonocito M, Spada RS, Benedetto FA. Plasma endothelin-1 release in normal and varicose saphenous veins. Angiology 1997; 48: 769–774CrossRefPubMedGoogle Scholar
  236. 236.
    Marin J, Reviriego J. Effect pf nicardipine on human placental vasculature. Arch Int Pharmacodyn Ther 1989; 302; 209–219PubMedGoogle Scholar
  237. 237.
    Marin J, Fernandez-Alfonso MS, Sanchez-Ferrer CF. Sodium pump activity and contractile effect of ouabain in human placental veins. Eur J Pharmacol 1991; 201: 75–82CrossRefPubMedGoogle Scholar
  238. 238.
    Martinez MC, Aldasoro M, Vila JM, Medina P, Lluch S. Responses to vasopressin and desmopressin of human cerebral arteries. J Pharmacol Exp Ther 1994; 270: 622–627PubMedGoogle Scholar
  239. 239.
    Mashiah A, Berman V, Thole HH, Rose SS, Pasik S, Schwarz H, Ben-Hur H. Estrogen and progesterone receptors in normal and varicose saphenous veins. Cardiovasc Surg 1999;7:327–331CrossRefPubMedGoogle Scholar
  240. 240.
    Masood I, Porter KE, London NJ. Endothelin-1 is a mediator of intimal hyperplasia in organ culture of human saphenous vein. Br J Surg 1997; 84: 499–503CrossRefPubMedGoogle Scholar
  241. 241.
    Mastrangelo D, Mathison R, Huggel H. Postjunctional localization of substance P receptors on the rat portal vein. Pharmacology 1983; 27: 305–318CrossRefPubMedGoogle Scholar
  242. 242.
    Matsumoto T, Tomita T. Intracellular alkahnization caused by chloride removal in the smooth muscle of guinea-pig vena cava. Jpn J Physiol 1993; 43: 67–73CrossRefPubMedGoogle Scholar
  243. 243.
    McCormack DG, Mak JC, Coupe MO, Barnes PJ. Calcitonin gene-related peptide vasodilation of human pulmonary vessels, J Appl Physiol 1989; 67: 1265–1270PubMedGoogle Scholar
  244. 244.
    McEwan JR, Benjamin N, Larkin S, Fuller RW, Dollery CT, Maclntyre I. Vasodilatation by calcitonin gene-related peptide and by substance P: a comparison of their effects on resistance and capacitance vessels of human forearms. Circulation 1988;77:1072–1080CrossRefPubMedGoogle Scholar
  245. 245.
    McGregor E, Gosling M, Beattie DK, Ribbons DM, Davies AH, Powell JT. Circumferential stretching of saphenous vein smooth muscle enhances vasoconstrictor responses by Rho kinase-dependent pathways. Cardiovasc Res 2002; 53: 219–226CrossRefPubMedGoogle Scholar
  246. 246.
    McKay MK, Hester RL. Role of nitric oxide, adenosine and ATP-sensitive potassium channels in insulin-induced vasodilation. Hypertension 1996; 28: 202–208CrossRefPubMedGoogle Scholar
  247. 247.
    McNamara, DB, Light JT, Minkes RK, Saroyan RM, Kvamme P, Rowe N, Webb WR, Fox L, Kersten MD, Mills NL, Kadowitz PJ. Comparative effects of endothelin (ET-1) and U 46619 on human saphenous vein and gastroepiploic artery, sources of human autologous grafts, Mol Cell Biochem. 1992; 117: 81–85CrossRefPubMedGoogle Scholar
  248. 248.
    Mehta P, Mehta J, Crews F, Roy L, Ostrowski N, Horalek C. Comparison of umbilical vein models from measurement of relative prostacyclin and thromboxane production. Prostaglandins 1982; 24: 743–749CrossRefPubMedGoogle Scholar
  249. 249.
    Mehta J, Roberts A. Human vascular tissue produce thromboxane as well as prostacyclin. Am J Physiol 1983; 244: R839–844PubMedGoogle Scholar
  250. 250.
    Mellander S, Andersson PO, Afzelius LE, Hellstrand P. Neural beta-adrenergic dilatation of the facial vein in man. Possible mechanism in emotional blushing. Acta Physiol Scand. 1982; 114: 393–399CrossRefPubMedGoogle Scholar
  251. 251.
    Metsarinne K, Saijonmaa O, Yki-Jarvinen H, Fyhrquist F. Insulin increases the release of endothelin in endothelial cell cultures in vitro but not in vivo. Metabolism 1994; 43: 878–882CrossRefPubMedGoogle Scholar
  252. 252.
    Michel JB, Feron O, Sase K, Prabhakar P, Michel T. Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 25907–25912CrossRefPubMedGoogle Scholar
  253. 253.
    Michiels C, Arnould T, Knott I, Dieu M, Remacle J. Stimulation of prostaglandin synthesis by human endothelial cells exposed to hypoxia. Am J Physiol 1993; 264: C866–874PubMedGoogle Scholar
  254. 254.
    Mikkelsen E, Andersson KE, Pedersen OL. Effects of digoxin on isolated human mesenteric vessels. Acta Pharmacol Toxicol 1979; 45: 25–31CrossRefGoogle Scholar
  255. 255.
    Mikkelsen E, Sakr AM, Jespersen LT, Studies on the effect of histamine in isolated human pulmonary arteries and veins, Acta Pharmacol Toxicol (Copenh) 1984; 54: 86–93CrossRefGoogle Scholar
  256. 256.
    Miller VM, Vanhoutte PM. Endothelial α2-adrenoceptors in canine pulmonary and systemic blood vessels. Eur J Pharmacol 1985; 118: 123–129CrossRefPubMedGoogle Scholar
  257. 257.
    Miller VM, Rud KS, Gloviczki P. Pharmacological assessment of adrenergic receptors in human varicose veins. Int Angiol 2000; 19: 176–183PubMedGoogle Scholar
  258. 258.
    Milesi V, Rebolledo A, Ayala Paredes F, Sanz N, Tommasi J, Rinaldi GJ, Grassi AO. Mechanical properties of human saphenous veins from normotensive and hypertensive patients. Ann Thorac Surg 1998; 66: 455–461CrossRefPubMedGoogle Scholar
  259. 259.
    Milton SG, Knutson VP. Insulin receptor characterization and function in bovine aorta endothelial cells: insulin degradation by a plasma membrane, protease-resistant insulin receptor. J Cell Physiol. 1993; 157: 333–343.CrossRefPubMedGoogle Scholar
  260. 260.
    Mizuno K, Niimura S, Tani SM, Haga H, Inagami T, Fukuchii S. Direct proof for local generation and release of angiotensin II in peripheral human vascular tissue. Am J Hypertens 1991; 4 (suppl): S67–72Google Scholar
  261. 261.
    Molderings GJ, Likungu J, Hentrich F, Gothert M. Facilitatory presynaptic angiotensin receptors on the sympathetic nerves of the human saphenous vein and pulmonary artery. Potential involvement in beta-adrenoceptor-mediated facilitation of noradrenaline release. Naunyn Schmiedebergs Arch Pharmacol 1988; 338: 228–233CrossRefPubMedGoogle Scholar
  262. 262.
    Molderings GJ, Werner K, Likungu J, Gothert M. Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein via presynaptic 5-HT receptors similar to the 5-HT 1D subtype. Naunyn Schmiedebergs Arch Pharmacol 1990; 342: 371–377CrossRefPubMedGoogle Scholar
  263. 263.
    Molderings GJ, Weissenborn G, Schlicker E, Likungu J, Göthert M. Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein by presynaptic histamine H3 receptors. Naunyn Schmiedebergs Arch Pharmacol 1992; 346: 46–50CrossRefPubMedGoogle Scholar
  264. 264.
    Molderings GJ, Colling E, Likungu J, Jakschik J, Gothert M. Modulation of noradrenaline release from the sympathetic nerves of the human saphenous vein and pulmonary artery by presynaptic EP3- and DP-receptors. Br J Pharmacol 1994; 111: 733–738CrossRefPubMedGoogle Scholar
  265. 265.
    Molderings GJ, Gothert M. Subtype determination of presynaptic alpha 2-autoreceptors in the rabbit pulmonary artery and human saphenous vein. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 483–490.CrossRefPubMedGoogle Scholar
  266. 266.
    Molenaar P, Malta E, Jones CR, Buxton BF, Summers RJ. Autoradiographic localization and function of beta-adrenoceptors on the human internal mammary artery and saphenous vein. Br J Pharmacol 1988; 95: 225–233CrossRefPubMedGoogle Scholar
  267. 267.
    Mombouli JV; Le SQ; Wasserstrum N; Vanhoutte PM. Endothelins 1 and 3 and big endothelin-1 contract isolated human placental veins. J Cardiovasc Pharmacol 1993; 22 (Suppl 8):S278–281CrossRefPubMedGoogle Scholar
  268. 268.
    Mombouli J-V, Vanhoutte PM. Endothelium-dependent hyperpolarizing factor(s): updating the unknown. Trends Pharmacol Sci 1997; 18: 252–256CrossRefPubMedGoogle Scholar
  269. 269.
    Moncada S, Rees DD, Schultz R, Palmer RMJ. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci USA 1991; 88: 2166–2170CrossRefPubMedGoogle Scholar
  270. 270.
    Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002–2012CrossRefPubMedGoogle Scholar
  271. 271.
    Monos E, Contney S, Cowley AW, Stekiel WJ. Effect of long-term tilt on mechanical and electrical properties of rat saphenous vein, Am J Physiol 1989; 256: H1185–1191PubMedGoogle Scholar
  272. 272.
    Monos E, Contney S, Cowley AW, Stekiel WJ. Axial extension of vein induces endothelium-dependent cell membrane hyperpolarization in the smooth muscle in vivo. Pfluegers Arch 1992; 384: 177–182Google Scholar
  273. 273.
    Monos E. How does the vein respond to pressure. NIPS 1993; 8: 124–128Google Scholar
  274. 274.
    Monos E, Berczi V, Nadasy G. Local Control of veins: Biomechanical, Metabolic and Humoral Aspects, Physiological Reviews 1995; 75: 616–619Google Scholar
  275. 275.
    Morcillo EJ, Cortijo J. Species differences in the responses of pulmonary vascular preparations to 5-hydroxytryptamine. Therapie 1999; 54: 93–97PubMedGoogle Scholar
  276. 276.
    Munro E, Patel M, Chan P, Betteridge L, Gallagher K, Schachter M, Wolfe J, Sever P. Effect of calcium channel blockers on the growth of human vascular smooth muscle cells derived from saphenous vein and vascular graft stenoses. J Cardiovasc Pharmacol 1994;23:779–784CrossRefPubMedGoogle Scholar
  277. 277.
    Murad E, Waldman S, Molina C, Bennett B, Leitman D. Regulation and role of guanylate cyclase-cyclic GMP in vascular relaxation. Prog Clin Biol Res 1987; 249: 65–76PubMedGoogle Scholar
  278. 278.
    Nadasy GL, Szekacs B, Juhasz I, Feher J, Kowach AGB, Monos E. Role of endothelium, oxygen and ionic milieu in the prostacyclin and thromboxane production of rat aortic tissue slices. Acta Physiol Hung 1991; 78: 77–87PubMedGoogle Scholar
  279. 279.
    Nakakita K. Peptidergic innervation in the cerebral blood vessels of the guinea pig: an immunohistochemical study. J Cereb Blood Flow Metab. 1990; 10: 819–826.CrossRefPubMedGoogle Scholar
  280. 280.
    Nakazato Y, Ohga A, Shigei T, Uematsu T. Extrinsic innervation of the canine abdominal vena cava and the origin of cholinergic vasoconstrictor nerves. J Physiol 1982; 328: 191–203PubMedGoogle Scholar
  281. 281.
    Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid recepotrs: structures, properties, and functions. Physiol Rev 1999; 79: 1193–1226PubMedGoogle Scholar
  282. 282.
    Naruse K, Sokabe M. Involvement of stretch-activated ion channels in Ca2+ mobilization to mechanical stretch in endothelial cells. Am J Physiol 1993;264: C1037–1044PubMedGoogle Scholar
  283. 283.
    Nath RG, Lokhandwala MF, McCalden TA. Evidence for presynaptic dopaminergic inhibition of noradrenergic transmission in the rat portal vein. Proc West Pharmacol Soc. 1983: 26: 377–379PubMedGoogle Scholar
  284. 284.
    Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995; 268: C799–822PubMedGoogle Scholar
  285. 285.
    Nemcova S, Gloviczki P, Rud KS, Miller VM. Cyclic nucleotides and production of prostanoids in human varicose veins. J Vasc Surg 1999; 30: 876–883CrossRefPubMedGoogle Scholar
  286. 286.
    Nguyen DH, Voss U, Brecht K, The effect of potassium on isolated bovine facial and human saphenous veins. Experientia Basel 1980; 36: 975–976CrossRefGoogle Scholar
  287. 287.
    Nishiyama M, Takahara Y, Masaki T, Nakajima N, Kimura S. Pharmacological heterogeneity of both endothelin ETA- and ETB-receptors in the human saphenous vein. Jpn J Pharmacol 1995; 69; 391–398 (abstract)CrossRefPubMedGoogle Scholar
  288. 288.
    Noll G, Buhler FR, Yang Z, Lüscher TF. Different potency of endothelium-derived relaxing factors against thromboxane, endothelin, and potassium chloride in intramyocardial porcine coronary arteries. J Cardiovasc Pharmacol. 1991; 18: 120–126CrossRefPubMedGoogle Scholar
  289. 289.
    Noll G, Lüscher TF. The endothelium in acute coronary syndromes. Eur Heart J 1998; 19(suppl C): C30–38PubMedGoogle Scholar
  290. 290.
    Ochiai M, Ohno M, Taguchi J, Hara K, Suma H, Isshiki T, Yamaguchi T, Kurokawa K. Responses of human gastroepiploic arteries to vasoactive substances: comparison withresponses of internal mammary arteries and saphenous veins. J Thorac Cardiovasc Surg 1992; 104: 453–458PubMedGoogle Scholar
  291. 291.
    Omar HA, Figueroa R, Omar RA, Tejani N, Wolin MS. Hydrogen peroxide and reoxygenation cause prostaglandin-mediated contraction of human placental arteries and veins. Am J Obstet Gynecol 1992; 167: 201–207PubMedGoogle Scholar
  292. 292.
    Omar HA, Ramirez R, Gibson M. Properties of a progesterone-induced relaxation in human placental arteries and veins. J Clin Endocrinol Metab 1995; 80: 370–373CrossRefPubMedGoogle Scholar
  293. 293.
    O’Neil GS, Chester AH, Allen SP, Luu TN, Tadjkarimi S, Ridley P, Khagani A, Musumeci F, Yacoub MH. Endothelial function of human gastroepiploic artery. Implications for its use as a bypass graft. J Thorac Cardiovasc Surg 1991; 102: 561–565PubMedGoogle Scholar
  294. 294.
    Opie LH. Pharmacological differences between calcium antagonists. Eur Heart J 1997; 18(supl. A): A71–79CrossRefPubMedGoogle Scholar
  295. 295.
    Orimo A, Inoue S, Ouchi Y, Orima H. Vascular smooth muscle cells possess estrogen receptor and respond to estrogen. Ann NY Acad Sci 1995; 748: 592–594CrossRefPubMedGoogle Scholar
  296. 296.
    Ortiz JL, Gorenne I, Cortijo J, Seller A, Labat C, Sarria B, Abram TS, Gardiner PJ, Morcillo E, Brink C. Leukotriene receptors on human pulmonary vascular endothelium. Br J Pharmacol 1995; 115: 1382–1386CrossRefPubMedGoogle Scholar
  297. 297.
    Ottillinger B, Greeske K. Rational therapy of chronic venous insufficiency - chances and limits of the therapeutic use of horse-chestnut seeds extract. BMC Cardiovascular Disorders 2001; 1: 5–10CrossRefPubMedGoogle Scholar
  298. 298.
    Ottosson AM, Josefsson M, Ahlner J. Inhibition of nisoldipine on bovine mesenteric arteries and veins and on human peripheral veins. Arzneimittelforschung. 1995;45: 777–780.PubMedGoogle Scholar
  299. 299.
    Oury T, Day BJ, Crapo JD. Extracellular superoxide dismutase in vessels of airways of humans and baboons. Free Radic Biol Chem 1996; 20: 957–965CrossRefGoogle Scholar
  300. 300.
    Öztürk Y, Melih Altan V, Yildizoglu-Ari N. Effects of Experimental Diabetes and Insulin on Smooth Muscle Functions. Pharm Rev 1996; 48: 70–100Google Scholar
  301. 301.
    Pacaud P, Loirand G, Mironneau C, Mironneau J. Noradrenaline activates a calcium-activated chloride conductance and increases the voltage-dependent calcium current in cultured single cells of rat portal vein. Br J Pharmacol 1989; 97: 139–146CrossRefPubMedGoogle Scholar
  302. 302.
    Pacaud P, Loirand G, Gregoire G, Mironneau C, Mironneau J. Calcium-dependence of the calcium-activated chloride current in smooth muscle cells of rat portal vein. Pflueeers Arch 1992; 421: 125–130CrossRefGoogle Scholar
  303. 303.
    Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327: 524–526.CrossRefPubMedGoogle Scholar
  304. 304.
    Panconesi A, Del Bianco PL, Franchi G, Anselmi B, Andreini R. Somatostatin. Peripheral venoconstrictive activity and interaction with monoamine in man. Regul Pept l987; 18:267–276CrossRefGoogle Scholar
  305. 305.
    Park TC, Harker CT, Edwards JM, Moneta GL, Taylor LM, Porter JM. Human saphenous vein grafts explanted from the arterial circulation demonstrate altered smooth-muscle and endothelial responses. J Vasc Surg 1993; 18: 61–69CrossRefPubMedGoogle Scholar
  306. 306.
    Paul M, Wagner J, Dzau VJ. Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J Clin Invest 1993; 91: 2058–2064CrossRefPubMedGoogle Scholar
  307. 307.
    Pawloski JT, Chapnick BM. Leukotrienes C4 and D4 are potent endothelium-dependent relaxing agents in canine splachnic venous capacitance vessels. Circ Res 1993; 73: 395–404CrossRefPubMedGoogle Scholar
  308. 308.
    Pernow J, Lundberg JM. Modulation of noradrenaline and neuropeptide Y (NPY) release in the pig kidney in vivo: involvement of alpha 2, NPY and angiotensin II receptors, Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 379–385.CrossRefPubMedGoogle Scholar
  309. 309.
    Perrot-Applanat M, Dacquet C, Finet M, Pichon MF, Milgrom E. Estradiol and progesterone action in human and rabbit saphenous veins. Proceedings of the Ninth International Congress of Endocrinolosv. Nice. France: 1992: 525.Google Scholar
  310. 310.
    Perrot-Applanat M, Deng M, Fernandez H, Lelaidier C, Meduri G, Bouchard P. Immunohistochemical localization of estradiol and progesterone receptors in human uterus throughout pregnancy: expression in endometrial blood vessels. J Clin Endocrinol Metab 1994; 78: 216–224CrossRefPubMedGoogle Scholar
  311. 311.
    Perrot-Applanat M, Cohen-Solal K, Milgrom E, Finet M. Progesterone receptor expression in human saphenous veins. Circulation 1995: 92: 2975–2983CrossRefPubMedGoogle Scholar
  312. 312.
    Perrot-Applanat M. Estrogen receptors in the cardiovascular system. Steroids 1996; 61: 212–215CrossRefPubMedGoogle Scholar
  313. 313.
    Poli E, Casoli C, Spaggiari I, Starcich R, Bertaccini G. Contractile effect of endothelin-2 on the isolated human saphenous vein. Arch Int Pharmacodyn Ther 1991; 313: 108–119PubMedGoogle Scholar
  314. 314.
    Preibisz JJ. Calcitonin Gene-Related Peptide and regulation of human cardiovascular homeostasis. Am J Hypertens 1993; 6: 434–450PubMedGoogle Scholar
  315. 315.
    Pneto D, Benedito S, Simonsen U, Nyborg NC. Regional heterogeneity in the contractile and potentiating effects of neuropeptide Y in rat isolated coronary arteries: modulatory action of the endothelium. Br J Pharmacol 1991;102: 754–758.CrossRefGoogle Scholar
  316. 316.
    Privat C, Stepien O, David-Dufilho M, Brunet A, Bedioui F, Marche P, Devynck J, Devynck MA. Superoxide release from interleukin-1B-stimulated human vascular cells: in situ electrochemical measurement. Free Radic Biol Med 1999; 27: 554–559CrossRefPubMedGoogle Scholar
  317. 317.
    Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 1996; 9: 432–436CrossRefPubMedGoogle Scholar
  318. 318.
    Racchi H, Irarrazabal MJ, Howard M, Moran S, Zalaquett R, Huidobro-Toro JP. Adenosine 5’-triphosphate and neuropeptide Y are co-transmitters in conjunction with noradrenaline in the human saphenous vein. Br J Pharmacol 1999; 126: 1175–1185CrossRefPubMedGoogle Scholar
  319. 319.
    Rajagopalan S, Meng XP, Ramasamy S, Harisson DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572–2579CrossRefPubMedGoogle Scholar
  320. 320.
    Ralevic V, Burnstock G. Roles of P2-Purinoceptors in the Cardiovascular System. Circulation 1991; 84: 1–10CrossRefPubMedGoogle Scholar
  321. 321.
    Regoli D, Boudon A, Fauchere JL. Receptors and antagonists for substance P and related peptides, Pharm Rev 1994; 46: 551–589PubMedGoogle Scholar
  322. 322.
    Regoli D, Jukic D, Gobeil F. Kinin Bl and B2 receptor antagonists and therapeutic perspectives. Therapie 1995; 50: 9–18PubMedGoogle Scholar
  323. 323.
    Regoli D, Pheng LH, Allogho SN, Nguyen-Le XK, Gobeil F. Receptors for kinins: from classical pharmacology to molecular biology. Immunopharmacology 1996; 33: 116–122CrossRefPubMedGoogle Scholar
  324. 324.
    Rehn D, Unkauf M, Klein, P, Jost, V, L’ucker PW. Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency. Arzneimittelforschung. 1996; 46: 483–487PubMedGoogle Scholar
  325. 325.
    Remie R, Coppes RP, Meurs H, Roffel AF, Zaagsma J. Characterization of presynaptic vascular muscarinic receptors inhibiting endogenous noradrenaline overflow in the portal vein of the freely moving rat, Br J Pharmacol. 1990; 99: 223–226.CrossRefPubMedGoogle Scholar
  326. 326.
    Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer 1994; 56: 681–688CrossRefPubMedGoogle Scholar
  327. 327.
    Reviriego J, Fernandez-Alfonso MS, Marin J. Actions of vasoactive drugs on human placental vascular smooth muscle. Gen Pharmacol 1990; 21:719–727CrossRefPubMedGoogle Scholar
  328. 328.
    Reviriego J, JM, Fernandez-Alfonso MS, Guerra P, Marin J. Effects of Ca2+ antagonists’ nifedipine and diltiazem on isolated human chorionic arteries and veins. J Cardiovasc Pharmacol 1990; 16: 128–138CrossRefPubMedGoogle Scholar
  329. 329.
    Rice TL. Treatment of esophageal varices. Clin Pharm 1989; 8: 122–131PubMedGoogle Scholar
  330. 330.
    Rizzi A, Quaglio D, Vasquez G, Mascoli F, Amadesi S, Calo G, Regoli D, Zamboni P. Effects of vasoactive agents in healthy and diseased human saphenous veins. J Vasc Surg 1998; 28: 855–861CrossRefPubMedGoogle Scholar
  331. 331.
    Rizzi A, Rizzi C, Amadesi S, Calo’ G, Varani K, Inamura N, Regoli D. Pharmacological characterisation of the first non-peptide bradykinin B2 receptor agonist FR 190997: an in vitro study on human, rabbit and pig vascular B2 receptors. Naunyn Schmiedeberes Arch Pharmacol 1999; 360: 361–367CrossRefGoogle Scholar
  332. 332.
    Rogerson FM, Chai SY, Schlawe I, Murray WK, Marley PD, Mendelsohn FA. Presence of angiotensin converting enzyme in the adventitia of large blood vessels. J Hypertens 1992; 10: 615–620CrossRefPubMedGoogle Scholar
  333. 333.
    Rorie DK, Rusch NJ, Shepherd JT, Vanhoutte PM, Tyce GM. Prejunctional inhibition of norepinephrine release caused by acetylcholine in the human saphenous vein. Circ Res 1981;49:337–41CrossRefPubMedGoogle Scholar
  334. 334.
    Roubos N, Rosenfeldt FL, Richards SM, Conyers RA, Davis BB. Improved preservation of saphenous vein grafts by the use of glyceryl trinitrate-verapamil solution during harvesting. Circulation 1995; 92: II31–36Google Scholar
  335. 335.
    Rubanyi GM, Vanhoutte PM. Heterogeneity of endothehum-dependent responses to acetylcholine in canine femoral arteries and veins. Blood vessels 1988; 25: 407–415Google Scholar
  336. 336.
    Rubanyi GM, Polokoff MA. Endothelins: Molecular Biology, Biochemistry, Pharmacology, Physiology, and Pathophysiology. Pharm Rev, 1994; 46: 328–394Google Scholar
  337. 337.
    Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D’Amico EB, El-Moalem H, Page SO, Richardson CD, Winters B, Marucci L, Schwinn DA. Subtype specific regulation of human vascular alpha(l)-adrenergic receptors by vessel bed and age. Circulation. 1999; 100: 2336–2343.CrossRefPubMedGoogle Scholar
  338. 338.
    Rudofsky G. Return Circulation and Norepinepherine: An Update. Paris: John Libbey Eurotext; 1991: 219–224.Google Scholar
  339. 339.
    Rump LC, von Kugelgen I. A study of ATP as a sympathetic cotransmitter in human saphenous vein. Br J Pharmacol 1994; 111: 65–72CrossRefPubMedGoogle Scholar
  340. 340.
    Rusch NJ, Wooldridge TA, Kulig CC, Almassi GH, Nicolosi AC, Olinger GN, Boerboom LE. Reactivity of human saphenous veins at arterial perfusion pressures. J Thorac Cardiovasc Surg 1995; 97: 1005–1012CrossRefGoogle Scholar
  341. 341.
    Russell KS, Haynes MP, Caulin-Glaser T, Rosneck J, Sessa WC, Bender JR. Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells. Effects on calcium sensitivity and NO release. J Biol Chem 2000; 275: E571–583CrossRefGoogle Scholar
  342. 342.
    Sabouni MH, Brown GL, Kotake AN, Douglas FL, Mustafa SJ. Effects of CGS-159434 on the relaxations produced by adenosine analogs in human blood vessels. Eur J Pharmacol 1990; 187: 525–530CrossRefPubMedGoogle Scholar
  343. 343.
    Saetrum Opgaard O, Gulbenkian S, Bergdahl A, Barroso CP, Andrade NC, Polak JM, Queiroz e Melo JQ, Edvinsson L. Innervation of human epicardial coronary veins: immunohistochemistry and vasomotility. Cardiovasc Res 1995; 29: 463–468PubMedGoogle Scholar
  344. 344.
    Saris JJ, van Dijk MA, Kroon I, Schalekamp MA, Danser AH. Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. Hypertension 2000; 35: 764–768CrossRefPubMedGoogle Scholar
  345. 345.
    Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin effects in humans. J Clin Invest 1995; 94: 2511–2515CrossRefGoogle Scholar
  346. 346.
    Schimke I, Griesmacher G, Weigel G, Holzhutter HG, Muller MM. Effects of reactive oxygen species on eicosanoid metabolism in human endothelial cells. Prostaglandins 1992; 43:281–292CrossRefPubMedGoogle Scholar
  347. 347.
    Schmalfuss CM, Chen LY, Bott JN, Staples ED, Mehta JL. Superoxide anion generation, superoxide dismutase activity, and nitric oxide release in human internal mammary artery and saphenous vein segments. J Cardiovasc Pharmacol Ther 1999; 4: 249–257CrossRefPubMedGoogle Scholar
  348. 348.
    Schmidt M, Kroger B, Jacob E., Seulberger H, Subkowski T, Otter R, Meyer T, Schmalzing G, Hillen H. Molecular characterization of human and bovine endothelin-converting enzyme (ECE-1). FEBS Lett, 1994; 356: 238–243CrossRefPubMedGoogle Scholar
  349. 349.
    Schoeffter P, Godfraind T. Histamine receptors in the smooth muscle of human internal mammary artery and saphenous vein. Pharmacol Toxicol 1989; 64: 64–71CrossRefPubMedGoogle Scholar
  350. Schror K, Schröder H. “Eicosanoids and Smooth Muscle Function”. In Pharmacology of Smooth Muscle. Szekeres L, Papp JGY, ed. Springer-Verlag, 1994; 127–154Google Scholar
  351. 351.
    Schuller-Petrovic S, Siedler S, Kern T, Meinhart J, Schmidt K, Brunner F. Imbalance between the endothelial cell-derived contracting factors prostacyclin and angiotensin II and nitric oxide/cyclic GMP in human primary varicosis. Br J Pharmacol 1997; 122: 772–778CrossRefPubMedGoogle Scholar
  352. 352.
    Schwartz LB, Radic ZS, O’Donohoe MK, Mikat EM, McCann RL, Hagen PO. Saphenous vein endothelium-dependent relaxation in patients with peripheral vascular disease. Ann Vasc Surg 1992; 6:425–432CrossRefPubMedGoogle Scholar
  353. 353.
    Sheehan DW, Fahri LE, Russell JA. Prolonged lobar hypoxia in vivo enhances the responsivity of isolated pulmonary veins to hypoxia. Am Rev Respir Dis 1992; 145: 640–645PubMedGoogle Scholar
  354. 354.
    Shimada K, Matsushita Y, Wakabayashi K, Takahashi M, Matsubara A, Iijima A, Tanzawa K. Cloning and functional expression of endothelin-converting enzyme cDNA. Biochem Biophys Res Commun 1995; 207: 807–812CrossRefPubMedGoogle Scholar
  355. 355.
    Shimokawa H, Flavahan NA, Vanhoutte PM. Natural course of the impairment of endothelium-dependent relaxations after baloon endothelium removal in porcine coronary arteries. Possible dysfunction of an apertussis toxin-sensitive G protein. Circ Res 1989; 65: 740–753CrossRefPubMedGoogle Scholar
  356. 356.
    Shukla A, Rasik AM, Dhawan BN. Asiaticoside-induced elevation of antioxidant levels in healing wounds. Phytother Res 1999; 13: 50–54CrossRefPubMedGoogle Scholar
  357. 357.
    Sidawy AN, Hakim FS, Neville RF, Korman LY. Autoradiographic mapping and characterization of insulin-like growth factor-I receptor binding in human greater saphenous vein. J Vasc Surg 1993; 18: 947–952CrossRefPubMedGoogle Scholar
  358. 358.
    Sinzinger H, Fitscha P. Prostacyclin contracts normal and varicose human saphenous veins. Vasa 1984; 13: 228–230PubMedGoogle Scholar
  359. 359.
    Sinzinger H. The effect of dihydroergotamine on various platelet function tests and venous prostacyclin-formation in men. Thromb Haemost 1985; 53: 285–286.PubMedGoogle Scholar
  360. 360.
    Siska I-R, Avram J., Crisnic D, Tanasie G, Tatu C, Bunu C, Schneider Fr. Magnesium modulates human saphenous vein smooth muscle contractility. Proceedings of the 3rd International Symposium on Metal Elements in Environment, Medicine and Biology; Timisoara-Romania, October 26–28, 1998. Z. Gârban, P. Dragan, ed. Eurobit Publishing House Timisoara-Romania, 1998; 353–358Google Scholar
  361. 361.
    Siska I. -R., Avram J, Tatu C, Tanasie G, Bunu C. In vitro evaluation of smooth muscle contractility and endothelium function in primary varicose veins. Physiol Res 1999; 48(suppl. l):S118Google Scholar
  362. 362.
    Siska I-R, Avram J, Tatu C, Bunu C, Schneider Fr, Maties R. “Some aspects concerning the antioxidant capacity of venous blood in lower limbs varicose veins”. In Oxygen Transport to Tissue XXI. D. Delpy, A. Eke, ed. Kluwer Academic/Plenum Publishers NY, 1999: 445–452CrossRefGoogle Scholar
  363. 363.
    Smith K, Connaughton S, Docherty JR. Investigations of the subtype of alpha 2-adrenoceptor mediating contractions of the human saphenous vein. Br J Pharmacol 1992; 106:447–451CrossRefPubMedGoogle Scholar
  364. 364.
    Sneddon P, Westfall TD, Todorov LD, Mihaylova-Todorova S, Westfall DP, Kennedy C. Modulation of purinergic neurotransmission. Prog Brain Res 1999; 120: 11–20CrossRefPubMedGoogle Scholar
  365. 365.
    Sogo N, Campanella C, Webb DJ, Megson IL. S-Nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br J Pharmacol 2000; 131: 1236–1244CrossRefPubMedGoogle Scholar
  366. 366.
    Sohn H-Y, Keller M, Gloe T, Morawitz H, Rueckschloss U, Pohl U. The small G-protein Rac mediates depolarization-induced formation in human endothelial cells. J Biol Chem 2000; 275: 18745–18750CrossRefPubMedGoogle Scholar
  367. 367.
    Somlyo Apm Somlyo AV, Shuman H. Electron probe analysis of vascular smooth muscle. Composition of mitochondria, nuclei, and cytoplasm. J Cell Biol 1979; 81: 316–335CrossRefPubMedGoogle Scholar
  368. 368.
    Sparks HV. “Effect of local metabolic factors on vascular smooth muscle”. In Handbook of Physiology. The Cardiovascular System. Vascular Smooth Muscle. Volume II. Bethesda, MD: Am Physiol Soc 1980; 475–513Google Scholar
  369. 369.
    Stanke F, Cracowski JL, Chavanon O, Magne JL, Blin D, Bessard G, Devillier P. Glibenclamide inhibits thromboxane A2-induced contraction in human internal mammary artery and saphenous vein. Eur J Pharmacol 1998; 341: 65–71CrossRefPubMedGoogle Scholar
  370. 370.
    Stanke F, Devillier P, Breant D, Chavanon O, Sessa C, Bricca G, Bessard G. Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscle. Br J Clin Pharmacol 1998; 46: 571–575CrossRefPubMedGoogle Scholar
  371. 371.
    Steinberg HM, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. J Clin Invest 1994; 94: 1172–1179CrossRefPubMedGoogle Scholar
  372. 372.
    Stones RW; Beard RW; Burnstock G. Pharmacology of the human ovarian vein: responses to putative neurotransmitters and endothelin-1. Br J Obstet Gynaecol 1994; 101:701–706CrossRefPubMedGoogle Scholar
  373. 373.
    Strachan FE; Haynes WG; Webb DJ. Endothelium-dependent modulation of venoconstriction to sarafotoxin S6c in human veins in vivo. J Cardiovasc Pharmacol 1995;26(Suppl 3):S180–182PubMedGoogle Scholar
  374. 374.
    Stralin P, Karlsson K, Johansson BO, Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 1995; 15: 2032–2036CrossRefPubMedGoogle Scholar
  375. 375.
    Strobel WM, Lüscher TF, Simper D, Linder L, Haefeli WE. Substance P in human hand veins in vivo: tolerance, efficacy, potency, and mechanism of venodilator action. Clin Pharmacol Ther 1996; 60: 435–443CrossRefPubMedGoogle Scholar
  376. 376.
    Sundaresan M, Zu-Xi Y, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H202 for platelet-derived growth factor signal transduction. Science 1995; 270: 296–299CrossRefPubMedGoogle Scholar
  377. 377.
    Suzuki S., Takeshita A, Imaizumi T, Hirooka Y, Yoshida M, Ando S. Biphasic forearm vascular responses to intraarterial arginine vasopressin. J Clin Invest 1989; 84: 427–434CrossRefPubMedGoogle Scholar
  378. 378.
    Szabo C, Berczi V, Schneider F, Kovacs AGB, Monos E. Role of endothelium in the response of the vein wall to magnesium withdrawal. Pflugers Arch 1992; 420: 140–145CrossRefPubMedGoogle Scholar
  379. 379.
    Tadjkarimi S, O’Neil GS, Luu TN, Allen SP, Schyns CJ, Chester AH, Yacoub MH. Comparison of cyclic GMP in human internal mammary artery and saphenous vein: implications for coronary artery bypass graft patency, Cardiovasc Res 1992; 26: 297–300CrossRefPubMedGoogle Scholar
  380. 380.
    Tackett RL, Zumbro G, Rubin J. Increased superoxide production in vasculature of African Americans impairs endothelial-mediated relaxation. Circulation 1997; 97: 1–375 (abstract)Google Scholar
  381. 381.
    Thorin-Trescases N, Hamilton CA, Reid JL, McPherson KL, Jardine E, Berg G, Bohr D, Dominiczak AF. Inducible L-arginine/nitric oxide pathway in human internam mammary artery and saphenous vein. Am J Physiol 1995; 268: H1122–1132PubMedGoogle Scholar
  382. 382.
    Thulesius O, Said S, Shuhaiber H, Neglen P, Gjores JE. Endothelial mediated enhancement of noradrenaline-induced vasoconstriction in normal and varicose veins. Clin Physiol 1991; 11: 153–159CrossRefPubMedGoogle Scholar
  383. 383.
    Tirupattur PR, Ram JL, Standley PR, Sowers JR. Regulation of Na+K+-ATPase gene expression by insulin in vascular smooth muscle cells. Am J Hypertens. 1993;6: 626–629.CrossRefPubMedGoogle Scholar
  384. 384.
    Toda N, Kimura T, Okamura T. Nitroxidergic nerve stimulation relaxes human uterine vein. J Auton Nerv Syst 1995; 55: 189–192CrossRefPubMedGoogle Scholar
  385. 385.
    Toda N; Yoshida K; Okamura T. Involvement of nitroxidergic and noradrenergic nerves in the relaxation of dog and monkey temporal veins, J Cardiovasc Pharmacol 1995; 25; 741–747CrossRefPubMedGoogle Scholar
  386. 386.
    Tornebrandt K, Nobin A, Owman C. Contractile and dilatory action of neuropeptides on isolated human mesenteric blood vessels. Peptides 1987; 8: 251–256CrossRefPubMedGoogle Scholar
  387. 387.
    Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639–672PubMedGoogle Scholar
  388. 388.
    Tripodi F, Stanke-Labesque F, Devillier P, Chavanon O, Sessa C, Bessard G. Antagonistic effects of losartan on thromboxane A2-receptors in human isolated gastroepiploic artery and saphenous vein. J Cardiovasc Pharmacol 1999; 34: 734–740CrossRefPubMedGoogle Scholar
  389. 389.
    Tsuru H, Matsukado Y, Shigei T. Evidence for the excitatory cholinergic innervation in the rabbit portal vein. Jpn J Pharmacol 1994; 66: 393–396CrossRefPubMedGoogle Scholar
  390. 390.
    Urakami-Harasawa L, Shimokawa H, Nakashima H, Egashira K, Takeshira A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest 1996; 100: 2793–2799CrossRefGoogle Scholar
  391. 391.
    Vajo Z, Szekacs B, Dachman W. Evidence for genetic variability in venous responsiveness. Acta Physiol Hung 1996; 84: 353–360PubMedGoogle Scholar
  392. 392.
    Vallance P, Collier J, Moncada S. Nitric oxide synthesized from L-arginine mediates endothelium dependent dilation in human veins in vivo. Cardiovasc Res 1989; 23: 1053–1057CrossRefPubMedGoogle Scholar
  393. 393.
    Van Renterghem C, Lazdunski M. A new non-voltage-dependent, epithelial-like Na+ channel in vascular smooth muscle cells. Pfluegers Arch 1991; 419: 401–408CrossRefGoogle Scholar
  394. 394.
    Vanhoutte PM, Janssens WJ. Local control of venous function,. Microvasc Res 1978; 16: 144–146CrossRefGoogle Scholar
  395. 395.
    Vanhoutte PM, Shepherd JT. Muscarinic and beta-adrenergic prejunctional modulation of adrenergic neurotransmission in the blood vessel wail. Gen Pharmacol 1983; 14: 35–37CrossRefPubMedGoogle Scholar
  396. 396.
    Vanhoutte PM. The role of the systemic veins: an update. Phlebology 1988; 3(suppl. 1): 13–25Google Scholar
  397. 397.
    Vanhoutte PM, Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989; 80: 1–9CrossRefPubMedGoogle Scholar
  398. 398.
    Vanhoutte PM, Lüscher TF, Graser T. Endothelium dependent contractions. Blood vessels 1991;28:74–83PubMedGoogle Scholar
  399. 399.
    Vashisht R, Sian M, Sharp EJ, Leathard HL, O’Malley MK. Serotonin-induced contractility in human saphenous vein is inhibited by naftidrofuryl. Br J Surg 1992; 79: 1154–1156CrossRefPubMedGoogle Scholar
  400. 400.
    Vedernikov YP, Graser T, Tiedt N, Vikhert M. Heterogeneity of the response of venous smooth muscle to arterial endothelium-derived relaxing factor (EDRF) in respect of the role of nitric oxide. Basic Res Cardiol 1988; 83: 122–127CrossRefPubMedGoogle Scholar
  401. 401.
    Verbeuren TJ, Lopez RR, Aarhus LL, Shepherd TJ, Vanhoutte PM. Prejunctional beta-adrenoceptors in human and canine saphenous veins. J Anatomic Nervous System 1983;8:261–271CrossRefGoogle Scholar
  402. 402.
    Verma S, Lovren F, Dumont AS, Mather KJ, Maitland A, Kieser TM, Triggle CR, Anderson TJ. Tetrahydrobiopterin improves endothelial function in human saphenous veins. J Thorac Cardiovasc Sure 2000; 120: 668–671CrossRefGoogle Scholar
  403. 403.
    Vesely DL. Atrial Natriuretic Peptides. Kidney: A Current Survey of World Literature, 1994; 3: 4–8Google Scholar
  404. 404.
    Walch L, Taisne C, Gascard JP, Nashashibi N, Brink C, Norel X. Cholinesterase activity in human pulmonary arteries and veins. Br J Pharmacol 1997; 121: 986–990CrossRefPubMedGoogle Scholar
  405. 405.
    Walch L, Norel X, Gascard JP, Brink C. Cysteinyl-leukotnene receptors in pulmonary vessels. J Physiol Pharmacol 1999; 50: 567–573PubMedGoogle Scholar
  406. 406.
    Walch L, Norel X, Leconte B, Gascard JP, Brink C. Cholinergic control of human and animal pulmonary vascular tone. Therapie 1999; 54: 99–102PubMedGoogle Scholar
  407. 407.
    Walch L, Gascard JP, Dulmet E, Brink C, Norel X. Evidence for a M1 muscarinic receptor on the endothelium of human pulmonary veins. Br J Pharmacol 2000; 130: 73–78CrossRefPubMedGoogle Scholar
  408. 408.
    Walch L, de Montpreville V, Brink C, Norel X.Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol. 2001; 134: 1671–1678.CrossRefPubMedGoogle Scholar
  409. 409.
    Wali FA, Suer AH, Greenidge E. Verapamil, diltiazem and nifedipine inhibit vascular responses to noradrenaline, acetylcholine and 5-hydroxytryptamine in human saphenous vein. Pharmacol Res Commun 1986; 18:1123–1138CrossRefPubMedGoogle Scholar
  410. 410.
    Wali FA, Greenridge E, Tugwell AC. Effect of verapamil on the contraction produced by high potassium and by noradrenaline in human isolated saphenous vein. Acta Physiol Hung 1988; 72: 115–121PubMedGoogle Scholar
  411. 411.
    Wallerstedt SM, Bodelsson M. Endothelium-dependent relaxation by substance P in human isolated omental arteries and veins: relative contribution of prostanoids, nitric oxide and hyperpolarization. Br J Pharmacol 1997; 120: 25–30CrossRefPubMedGoogle Scholar
  412. 412.
    Wang Q, Hogg RC, Large WA. Properties of spontaneous inward currents recorded in smooth muscle cells isolated from the rabbit portal vein. J Physiol Lond 1992; 451: 525–537PubMedGoogle Scholar
  413. 413.
    Webb DJ, Benjamin N, Allen MJ, Brown J, O’Flynn M, Cockcroft JR. Vascular responses to local atrial natriuretic peptide infusion in man. Br J Clin Pharmac 1988; 26:245–251CrossRefGoogle Scholar
  414. 414.
    Webb DJ, Benjamin N, Cockcroft JR, Collier JG. Augmentation of sympathetic venoconstriction by angiotensin II in human dorsal hand veins. Am J Hypertens 1989; 2: 721–723CrossRefPubMedGoogle Scholar
  415. 415.
    Weiner N, Molinoff PB, “Catecholamines” In Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 4th edition. Siegel GJ et al., ed. Raven Press NY, 1989; 233–251Google Scholar
  416. 416.
    Weinstein JS, Grossman W, Weintraub RM, Thurer RL, Johnson RG, Morgan KG. Differences in alpha-adrenergic responsiveness between human internal mammary arteries and saphenous veins. Circulation 1989; 79: 1264–1267CrossRefPubMedGoogle Scholar
  417. 417.
    Wenzel RR, Noll G, Lüscher TF. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 1994; 23: 581–586CrossRefPubMedGoogle Scholar
  418. 418.
    West NEJ, Guzik TJ, Black E, Channon KM. Enhanced superoxide production in experimental venous bypass graft intimal hyperplasia. Role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2001; 21: 189–194CrossRefPubMedGoogle Scholar
  419. 419.
    White DG, Garratt H, Mundin JW, Sumner MJ, Vallance PJ, Watts IS. Human saphenous vein contains both endothelin ETA and ETB contractile receptors. Eur J Pharmacol 1994;257:307–310CrossRefPubMedGoogle Scholar
  420. 420.
    Wolin MS. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol 2000; 20: 1430–1442CrossRefPubMedGoogle Scholar
  421. 421.
    Woods M, Bishop-Bailey D, Pepper JR, Evans TW, Mitchell JA, Warner TD. Cytokine and lipopolysaccharide stimulation of endothelin-1 release from human internal mammary artery and saphenous vein smooth-muscle cells, J Cardiovasc Pharmacol 1998; 83: S348–350CrossRefGoogle Scholar
  422. 422.
    Yang JA, He GW. Surgical preparation abolishes endothelium-derived hyperpolarizing factor-mediated hyperpolarization in the human saphenous vein. Ann Thorac Surg 1997; 63: 429–433CrossRefPubMedGoogle Scholar
  423. 423.
    Yang Z, Luscher TF. Endothelium-dependent regulatory mechanisms in human coronary bypass grafts: possible clinical implications. Z Kardiol. 1989;78 Suppl 6: 80–84PubMedGoogle Scholar
  424. 424.
    Yang ZH, Diederich D, Schneider K, Siebenmann R, Stulz P, von Segesser L, Turina M, Bühler FR, Lüscher TF. Endothelium-derived relaxing factor and protection against contractions induced by histamine and serotonin in the human internal mammary artery and in the saphenous vein. Circulation 1989; 80:1041–1048CrossRefPubMedGoogle Scholar
  425. 425.
    Yang ZH, Bühler FR, Diederich D, Lüscher TF. Different effects of endothelin-1 on cAMP- and cGMP-mediated vascular relaxation in human arteries and veins: comparison with norepinephrine. J Cardiovasc Pharmacol 1989; 13 (Suppl 5): S129–123CrossRefPubMedGoogle Scholar
  426. 426.
    Yang ZH, von Segesser L, Bauer E, Stulz P, Turina M, Lüscher TF. Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res 1991; 68: 52–60CrossRefPubMedGoogle Scholar
  427. 427.
    Yang Z, Arnet U, von Segesser L, Siebenmann R, Turina M, Lüscher TF. Different effects of angiotensin-converting enzyme inhibition in human arteries and veins. J Cardiovasc Pharmacol 1993; 22 (suppl 5): S17–22CrossRefPubMedGoogle Scholar
  428. 428.
    Yang Z, Lüscher TF. Basic cellular mechanisms of coronary bypass graft disease, Eur Heart J 1993; 14 (suppl 1): 193–197Google Scholar
  429. 429.
    Yang Z, Ruschitzka F, Rabelink TJ, Noll G, Julmy F, Joch H, Gafner V, Aleksic I, Althaus U, Lüscher TF. Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels implications for venous bypass graft failure. Circulation. 1997; 95: 1870–1876CrossRefPubMedGoogle Scholar
  430. 430.
    Yatani A, Seidel CL, Allen J, Brown AM. Whole-cell and single-cell calcium currents of isolated smooth muscle cells from saphenous vein. Curc Res 1987; 60: 523–533CrossRefGoogle Scholar
  431. 431.
    Yoshioka K, Furuta T, Hayakawa A, Ishikawa N, Shigei T. Excitatory cholinergic innervation in canine portal and mesenteric veins. Am J Physiol 1988; 255: H288–294.PubMedGoogle Scholar
  432. 432.
    Yu JC, Davenport AP. Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells. Br J Pharmacol 1995: 114: 551–557CrossRefPubMedGoogle Scholar
  433. 433.
    Zhang LM, Castresana MR, McDonald MH, Johnson JH, Newman WH. Response of human artery, vein, and cultured smooth muscle cells to atrial and C-type natriuretic peptides. Crit Care Med 1996; 24: 306–310CrossRefPubMedGoogle Scholar
  434. 434.
    Zhao Y, Packer CS, Rhoades RA. Pulmonary vein contracts in response to hypoxia. Am J Physiol 1993; 265: L87–92PubMedGoogle Scholar
  435. 435.
    Zhao Y, Packer CS, Rhoades RA. Chronic hypoxia impairs pulmonary venous smooth muscle contraction. Respir Physiol 1995; 100: 75–82CrossRefPubMedGoogle Scholar
  436. 436.
    Zhao M, Bo X, Burnstock G. Distribution of [3H] alpha, beta-methylene ATP binding sites in pulmonary blood vessels of different species. Pulm Pharmacol 1996; 9: 167–174CrossRefPubMedGoogle Scholar
  437. 437.
    Zhao L, Tackett RL. Oxidized low-density lipoprotein inhibits acetylcholine-induced vasorelaxation and increases 5-HT-induced vasoconstriction in isolated human saphenous vein. J Pharmacol Exp Ther 1998; 284: 637–643.PubMedGoogle Scholar
  438. 438.
    Zurowska-Grojec Z, Pruszcyk P, Colton C, Yao J, Shen GH, Myers AK, Wahlestedt C. Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. Peptides 1993; 14: 263–268CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Francisc A. Schneider
    • 1
    • 2
  • Ioana Raluca Siska
    • 2
  • Jecu Aurel Avram
    • 2
  1. 1.Western University “Vasile Goldiş” Arad University of Medicine and PharmacyTimisoara
  2. 2.University of Medicine and PharmacyTimisoara

Personalised recommendations